View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2013	Aug. 05, 2013
Document - Document and Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	ARWR
Entity Registrant Name	ARROWHEAD RESEARCH CORPORATION
Entity Central Index Key	0000879407
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		31,539,199

Consolidated Balance Sheets - USD ($)	Jun. 30, 2013	Sep. 30, 2012
CURRENT ASSETS
Cash and cash equivalents	$ 29,025,930	$ 3,377,288
Trade receivable		9,375
Other receivables	267,560	9,930
Prepaid expenses and other current assets	1,059,503	618,130
Short term investments	4,058,003	106,500
Note receivable, net		2,446,113
TOTAL CURRENT ASSETS	34,410,996	6,567,336
PROPERTY AND EQUIPMENT
Computers, office equipment and furniture	323,376	323,376
Research equipment	3,346,789	3,319,027
Software	69,623	69,623
Leasehold improvements	2,749,409	2,749,409
Property, Plant and Equipment, Gross, Total	6,489,197	6,461,435
Less: Accumulated depreciation and amortization	(2,695,886)	(1,565,783)
PROPERTY AND EQUIPMENT, NET	3,793,311	4,895,652
OTHER ASSETS
Patents and other intangible assets, net	3,254,177	4,784,569
Derivative asset and other non-current assets	30,011	280,261
TOTAL OTHER ASSETS	3,284,188	5,064,830
TOTAL ASSETS	41,488,495	16,527,818
CURRENT LIABILITIES
Accounts payable	1,061,944	877,986
Accrued expenses	706,092	730,775
Accrued payroll and benefits	811,046	1,127,219
Deferred revenue	71,875	37,500
Derivative liabilities	2,335,163	647,213
Capital lease obligation	219,690	214,801
Notes payable	925,649	100,000
Other current liabilities	546,407	1,592,394
TOTAL CURRENT LIABILITIES	6,677,866	5,327,888
LONG-TERM LIABILITIES
Notes payable, net of current portion	50,000	839,421
Capital lease obligation, net of current portion	1,117,074	1,282,458
Other non-current liabilities	337,587	269,142
TOTAL LONG-TERM LIABILITIES	1,504,661	2,391,021
Commitments and contingencies
STOCKHOLDERS’ EQUITY
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 9,900 shares issued and outstanding	10
Common stock, $0.001 par value; 145,000,000 shares authorized; 31,306,318 and 13,579,185 shares issued and outstanding as of June 30, 2013 and September 30, 2012, respectively	123,665	108,354
Additional paid-in capital	187,282,079	145,917,968
Subscription receivable		(1,016,000)
Accumulated deficit during the development stage	(152,448,785)	(134,997,680)
Total Arrowhead Research Corporation stockholders' equity	34,956,969	10,012,642
Noncontrolling interest	(1,651,001)	(1,203,733)
TOTAL STOCKHOLDERS’ EQUITY	33,305,968	8,808,909
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 41,488,495	$ 16,527,818

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2013	Sep. 30, 2012
Statement - Consolidated Balance Sheets (Parenthetical) [Line Items]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	9,900	9,900
Preferred stock, shares outstanding	9,900	9,900
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	145,000,000	145,000,000
Common stock, shares issued	31,306,318	13,579,185
Common stock, shares outstanding	31,306,318	13,579,185

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		122 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Statement - Consolidated Statements of Operations [Line Items]
REVENUE	$ 43,750	$ 47,917	$ 246,516	$ 103,125	$ 4,385,350
OPERATING EXPENSES
Salaries and payroll-related costs	1,651,729	1,654,915	5,006,328	4,992,671	31,398,458
General and administrative expenses	899,633	3,137,368	2,597,279	5,335,191	33,950,494
Research and development	1,756,527	1,219,236	5,458,212	3,347,002	48,076,960
Stock-based compensation	363,593	415,920	1,114,375	837,188	14,695,843
Depreciation and amortization	454,086	423,414	1,352,448	1,301,806	8,761,734
Impairment expense	1,308,047		1,308,047		1,308,047
TOTAL OPERATING EXPENSES	6,433,615	6,850,853	16,836,689	15,813,858	138,191,536
OPERATING LOSS	(6,389,865)	(6,802,936)	(16,590,173)	(15,710,733)	(133,806,186)
OTHER INCOME (EXPENSE)
Equity in income (loss) of unconsolidated affiliates	(159,530)	(34,573)	(380,699)	(205,361)	(1,344,106)
Impairment of investment in unconsolidated affiliates		(1,455,775)		(1,455,775)	(1,642,775)
Gain on purchase of Roche Madison				1,576,107	1,576,107
Gain (loss) on sale of fixed assets, net	(39,949)	(876,277)	(76,388)	(909,761)	(1,282,853)
Realized and unrealized gain (loss) investments				(58,091)	62,954
Interest income (expense), net	(48,252)	14,436	(68,403)	27,326	2,682,041
Change in value of derivatives	200,747	915,387	215,620	226,339	3,497,024
Gain on sale of stock in subsidiary
Other income (expense)	259,221		(997,976)		(747,976)
TOTAL OTHER INCOME (EXPENSE)	212,237	(1,436,802)	(1,307,846)	(799,216)	5,093,216
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(6,177,628)	(8,239,738)	(17,898,019)	(16,509,949)	(128,712,970)
Provision for income taxes
LOSS FROM CONTINUING OPERATIONS	(6,177,628)	(8,239,738)	(17,898,019)	(16,509,949)	(128,712,970)
Income (loss) from discontinued operations		677	(354)	(25)	(47,546,996)
Gain on disposal of discontinued operations					4,708,588
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS		677	(354)	(25)	(42,838,408)
NET LOSS	(6,177,628)	(8,239,061)	(17,898,373)	(16,509,974)	(171,551,378)
Net (income) loss attributable to noncontrolling interests	98,618	247,551	447,268	697,727	19,266,553
NET LOSS ATTRIBUTABLE TO ARROWHEAD	$ (6,079,010)	$ (7,991,510)	$ (17,451,105)	$ (15,812,247)	$ (152,284,825)
NET LOSS PER SHARE ATTRIBUTABLE TO ARROWHEAD SHAREHOLDERS - BASIC AND DILUTED:	$ (0.23)	$ (0.71)	$ (0.92)	$ (1.48)
Weighted average shares outstanding - basic and diluted	26,134,183	11,238,291	18,893,197	10,672,390

Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common Stock	Preferred Stock	Additional Paid-in Capital	Subscriptions Receivable	Accumulated Deficit during Development Stage	Noncontrolling Interest	Issued For Cash At Zero Point Zero One Dollars Per Unit	Issued For Cash At Zero Point Zero One Dollars Per Unit Common Stock	Issued For Cash At Ten Dollar Per Unit	Issued For Cash At Ten Dollar Per Unit Common Stock	Issued For Cash At Ten Dollar Per Unit Additional Paid-in Capital	Issued For Marketable Securities At Ten Dollar Per Unit	Issued For Marketable Securities At Ten Dollar Per Unit Common Stock	Issued For Marketable Securities At Ten Dollar Per Unit Additional Paid-in Capital	Issued For Cash At Fifteen Dollar Per Unit	Issued For Cash At Fifteen Dollar Per Unit Common Stock	Issued For Cash At Fifteen Dollar Per Unit Additional Paid-in Capital	Equity Issued in Business Combination	Equity Issued in Business Combination Common Stock	Equity Issued in Business Combination Additional Paid-in Capital	Issued As Gift For Ten Dollar And Ninety Cents Per Share	Issued As Gift For Ten Dollar And Ninety Cents Per Share Common Stock	Issued As Gift For Ten Dollar And Ninety Cents Per Share Additional Paid-in Capital	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit Common Stock	Issued As Stock Issuance Cost At Fifteen Dollar Per Unit Additional Paid-in Capital	Exercised At Two Dollar Per Share	Exercised At Two Dollar Per Share Common Stock	Exercised At Two Dollar Per Share Additional Paid-in Capital	Exercised At Ten Dollar Per Share	Exercised At Ten Dollar Per Share Common Stock	Exercised At Ten Dollar Per Share Additional Paid-in Capital	Stock Issuance Cost Charged To Additional Paid In Capital	Stock Issuance Cost Charged To Additional Paid In Capital Additional Paid-in Capital	Exercised at $15.00 per share	Exercised at $15.00 per share Common Stock	Exercised at $15.00 per share Additional Paid-in Capital	Issued to purchase Insert Therapeutics share at $39.80 per share	Issued to purchase Insert Therapeutics share at $39.80 per share Common Stock	Issued to purchase Insert Therapeutics share at $39.80 per share Additional Paid-in Capital	Issued at $48.80 per share	Issued at $48.80 per share Common Stock	Issued at $48.80 per share Additional Paid-in Capital	Issued at $38.40 per share	Issued at $38.40 per share Common Stock	Issued at $38.40 per share Additional Paid-in Capital	Issued at $35.00 per share	Issued at $35.00 per share Common Stock	Issued at $35.00 per share Additional Paid-in Capital	Issued at $59.10 per share	Issued at $59.10 per share Common Stock	Issued at $59.10 per share Additional Paid-in Capital	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share Common Stock	Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share Additional Paid-in Capital	Issued at $57.80 per share, net	Issued at $57.80 per share, net Common Stock	Issued at $57.80 per share, net Additional Paid-in Capital	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share Common Stock	Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share Additional Paid-in Capital	Issued at approximately $18.00 per share, net	Issued at approximately $18.00 per share, net Common Stock	Issued at approximately $18.00 per share, net Additional Paid-in Capital	Issued at $27.20 per share to Rice University	Issued at $27.20 per share to Rice University Common Stock	Issued at $27.20 per share to Rice University Additional Paid-in Capital	Issued at $28.30 per share to purchase shares of Unidym, Inc.	Issued at $28.30 per share to purchase shares of Unidym, Inc. Common Stock	Issued at $28.30 per share to purchase shares of Unidym, Inc. Additional Paid-in Capital	Issued at $29.50 per share to purchase MASA Energy, LLC	Issued at $29.50 per share to purchase MASA Energy, LLC Common Stock	Issued at $29.50 per share to purchase MASA Energy, LLC Additional Paid-in Capital	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction Common Stock	Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction Additional Paid-in Capital	Issued at $21.80 per share	Issued at $21.80 per share Common Stock	Issued at $21.80 per share Additional Paid-in Capital	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares Common Stock	Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares Additional Paid-in Capital	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares Common Stock	Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares Additional Paid-in Capital	Issued at $3.00 per share	Issued at $3.00 per share Common Stock	Issued at $3.00 per share Additional Paid-in Capital	Arrowheads increase in proportionate share of Calandos equity	Arrowheads increase in proportionate share of Calandos equity Additional Paid-in Capital	Issued at $6.34 per share	Issued at $6.34 per share Common Stock	Issued at $6.34 per share Additional Paid-in Capital	Issued at $13.12 per share	Issued at $13.12 per share Common Stock	Issued at $13.12 per share Additional Paid-in Capital	Issued To Calando Stockholders In Exchange For Calando S Shares	Issued To Calando Stockholders In Exchange For Calando S Shares Common Stock	Issued To Calando Stockholders In Exchange For Calando S Shares Additional Paid-in Capital	Issued To Calando Stockholders In Exchange For Calando S Shares Noncontrolling Interest	Issued To Unidym Stockholders In Exchange For Unidyms Shares Common Stock	Issued To Unidym Stockholders In Exchange For Unidyms Shares Additional Paid-in Capital	Issued To Unidym Stockholders In Exchange For Unidyms Shares Noncontrolling Interest	Issued at $3.80 per share	Issued at $3.80 per share Common Stock	Issued at $3.80 per share Additional Paid-in Capital	Issued at $3.80 per share Subscriptions Receivable	Series D preferred stock issued for subscription in unidym	Series D preferred stock issued for subscription in unidym Subscriptions Receivable	Issuance of common stock for subscription Additional Paid-in Capital	Issuance of common stock for subscription Subscriptions Receivable	Issued at $3.70 per share	Issued at $3.70 per share Common Stock	Issued at $3.70 per share Additional Paid-in Capital	Issued at $4.00 per share	Issued at $4.00 per share Common Stock	Issued at $4.00 per share Additional Paid-in Capital	Issued at $6.23 per share	Issued at $6.23 per share Common Stock	Issued at $6.23 per share Additional Paid-in Capital	Issued at $5.11 per share	Issued at $5.11 per share Common Stock	Issued at $5.11 per share Additional Paid-in Capital	Issued at $2.76 per share	Issued at $2.76 per share Common Stock	Issued at $2.76 per share Additional Paid-in Capital	Issued at $2.76 per share Subscriptions Receivable	Issued Under Committed Capital Agreement Common Stock	Issued Under Committed Capital Agreement Additional Paid-in Capital	Issued at $2.26 per share	Issued at $2.26 per share Common Stock	Issued at $2.26 per share Additional Paid-in Capital	Issued at $2.12 per share	Issued at $2.12 per share Common Stock	Issued at $2.12 per share Additional Paid-in Capital	Issued at $4.49 per share	Issued at $4.49 per share Common Stock	Issued at $4.49 per share Additional Paid-in Capital	Issued at $1.83 per share	Issued at $1.83 per share Common Stock	Issued at $1.83 per share Additional Paid-in Capital	Preferred stock issued @ $1,000 per share	Preferred stock issued @ $1,000 per share Preferred Stock	Preferred stock issued @ $1,000 per share Additional Paid-in Capital
Issuance and sold of Common Stock									300,000		168,000
Ending Balance Shares at Sep. 30, 2003		468,000
Beginning Balance Amount at Sep. 30, 2002
Stock issuances								$ 3,000	$ 3,000	$ 1,680,000	$ 1,680	$ 1,678,320
Stock issuance cost charged to additional paid-in capital																																		$ (168,000)	$ (168,000)
Net income (loss)	(95,238)					(95,238)
Ending Balance Amount at Sep. 30, 2003	1,419,762	$ 4,680		1,510,320		(95,238)
Issuance and sold of Common Stock											47,500			50,000			660,879			70,553			15,000			35,623
Ending Balance Shares at Sep. 30, 2004		1,363,155
Stock options exercised		7,500																											7,500			600
Stock issuances										$ 475,000	$ 475	$ 474,525	$ 500,000	$ 500	$ 499,500	$ 9,913,182	$ 6,609	$ 9,906,573	$ (150,469)	$ 706	$ (151,175)	$ 162,750	$ 163	$ 162,587	$ 534,344	$ 356	$ 533,988							$ (96,500)	$ (96,500)
Stock issuance cost charged to additional paid-in capital	(991,318)			(991,318)
Net income (loss)	(751,255)					(2,528,954)	1,777,699
Ending Balance Amount at Sep. 30, 2004	11,227,149	$ 13,645		12,059,997		(2,624,192)	1,777,699
Stock options exercised, Amount	15,000	$ 75		14,925																								$ 15,000	$ 75	$ 14,925	$ 6,000	$ 6	$ 5,994
Stock-based compensation	175,653			175,653
Issuance and sold of Common Stock		1,250																																						50,226
Ending Balance Shares at Sep. 30, 2005		2,798,419
Stock options exercised																																2,500					1,381,289
Stock issuances	50,000	$ 12		49,988																																			$ 2,000,000	$ 502	$ 1,999,498
Net income (loss)	(6,733,427)					(6,854,918)	121,491
Ending Balance Amount at Sep. 30, 2005	28,026,657	$ 27,997		35,578,580		(9,479,110)	1,899,190
Stock options exercised, Amount																															$ 25,000	$ 25	$ 24,975			$ 20,719,335	$ 13,813	$ 20,705,522
Stock-based compensation	508,513			508,513
Adjustments to additional paid in capital, reallocation of noncontrolling interest	230,087			230,087
Issuance and sold of Common Stock																																											20,485			1,500			559,000			2,536			20,838
Ending Balance Shares at Sep. 30, 2006		3,414,359
Stock options exercised		11,579
Stock issuances																																										$ 1,000,000	$ 205	$ 999,795	$ 57,600	$ 15	$ 57,585	$ 19,545,000	$ 5,590	$ 19,539,410	$ 150,000	$ 25	$ 149,975	$ 1,077,333	$ 208	$ 1,077,125
Net income (loss)	(19,961,961)					(18,997,209)	(964,752)
Ending Balance Amount at Sep. 30, 2006	31,605,644	$ 34,156		59,113,369		(28,476,319)	934,438
Stock options exercised, Amount	341,537	$ 116		341,421
Stock-based compensation	1,369,478			1,369,478
Issuance and sold of Common Stock																																																										284,945			143,122
Ending Balance Shares at Sep. 30, 2007		3,861,042
Stock options exercised		18,616
Stock issuances																																																									$ 15,152,215	$ 2,849	$ 15,149,366	$ 5,400,000	$ 1,431	$ 5,398,569
Net income (loss)	(30,712,947)					(29,931,118)	(781,829)
Ending Balance Amount at Sep. 30, 2007	26,456,577	$ 38,622		84,672,783		(58,407,437)	152,609
Stock options exercised, Amount	434,727	$ 186		434,541
Stock-based compensation	2,175,544			2,175,544
Adjustments to additional paid in capital, reallocation of noncontrolling interest	2,401,394			2,401,394
Issuance and sold of Common Stock																																																																386,399			5,000			7,055			10,505			11,416			1,500
Ending Balance Shares at Sep. 30, 2008		4,293,452
Stock options exercised		10,536
Stock issuances																																																															$ 6,960,585	$ 3,867	$ 6,956,718	$ 136,000	$ 50	$ 135,950	$ 200,000	$ 71	$ 199,929	$ 310,000	$ 105	$ 309,895	$ 250,000	$ 114	$ 249,886	$ 32,700	$ 15	$ 32,685
Net income (loss)	(27,241,639)					(27,089,030)	(152,609)
Ending Balance Amount at Sep. 30, 2008	12,302,609	$ 42,950		97,756,126		(85,496,467)
Stock options exercised, Amount	290,027	$ 106		289,921
Stock-based compensation	3,187,397			3,187,397
Adjustments to additional paid in capital, reallocation of noncontrolling interest	1,720,962			1,720,962
Issuance and sold of Common Stock																																																																																		205,839			222,222			919,664
Ending Balance Shares at Sep. 30, 2009		5,641,177
Stock issuances																																																																																	$ 1,133,676	$ 2,059	$ 1,131,617	$ 1,158,333	$ 2,222	$ 1,156,111	$ 2,758,993	$ 9,197	$ 2,749,796
Net income (loss)	(19,308,392)					(19,308,392)
Ending Balance Amount at Sep. 30, 2009	4,857,936	$ 56,428		110,070,327	(300,000)	(104,968,819)
Stock-based compensation	2,676,170			2,676,170
Adjustments to additional paid in capital, reallocation of noncontrolling interest	16,297			16,297																																																																																						$ 2,120,250	$ 2,120,250
Reclassification of former Unidym mezzanine debt to equity	2,000,000			2,000,000
Issuance of Preferred Stock for Subscription in Unidym				300,000	(300,000)
Amortization of discount on Unidym Series D Preferred Stock				163,960		(163,960)
Issuance and sold of Common Stock		225,189																																																																																											508,343			659,299			122,000			15,318
Ending Balance Shares at Sep. 30, 2010		7,172,014
Stock options exercised		688
Stock issuances	1,066,050	$ 2,250		1,063,600			200																																																																																					$ 3,222,896	$ 5,083	$ 3,217,813	$ 3,698,671	$ 6,593	$ 3,692,078		$ 1,220	$ (160,667)	$ 159,447	$ 153	$ (1,435)	$ 1,282
Net income (loss)	(6,957,038)					(5,774,048)	(1,182,990)
Ending Balance Amount at Sep. 30, 2010	8,078,295	71,734		119,716,834		(110,742,867)	(967,406)
Stock options exercised, Amount	7,631	$ 7		7,624
Stock-based compensation	1,582,149			1,582,149
Issuance of Preferred Stock for Subscription in Unidym																																																																																																													$ 300,000	$ 300,000
Issuance of Unidym’s common stock to minority shareholders	300,000			245,345			54,655
Issuance and sold of Common Stock		8,656																																																																																																								1,458,917
Ending Balance Shares at Sep. 30, 2011		8,642,286
Stock options exercised		2,700
Stock issuances	43,279	$ 87		43,192																																																																																																					$ 4,643,684	$ 14,574	$ 4,629,110				$ 900,000	$ (900,000)
Net income (loss)	(3,492,399)					(3,128,885)	(363,514)
Ending Balance Amount at Sep. 30, 2011	12,564,167	86,422		127,476,435	(900,000)	(113,871,752)	(226,938)
Stock options exercised, Amount	13,884	$ 27		13,857
Stock-based compensation	1,404,640			1,404,640
Adjustments to additional paid in capital, reallocation of noncontrolling interest				(849,707)			849,707
Issuance of Preferred Stock for Subscription in Unidym	1,618,509			1,618,509
Issuance of Unidym’s common stock to minority shareholders	$ 254,275						254,275
Issuance and sold of Common Stock		15,511																		1,217,159																																																																																						138,158								675,000			100,000			83,211			97,831			2,260,869			68,926
Ending Balance Shares at Sep. 30, 2012		13,579,185
Stock options exercised	4,883	4,583
Stock issuances	$ 50,406	$ 16		50,390															$ 6,147,830	$ 9,332	$ 6,138,498																																																																																				$ 425,000	$ 1,382	$ 523,618	$ (100,000)					$ 2,247,750	$ 6,750	$ 2,241,000	$ 400,000	$ 1,000	$ 399,000	$ 500,001	$ 83	$ 499,918	$ 500,002	$ 98	$ 499,904	$ 5,796,240	$ 2,261	$ 5,809,979	$ (16,000)	$ 689	$ (689)													$ 1,015,000	$ 1	$ 1,014,999
Net income (loss)	(22,110,723)					(21,125,928)	(984,795)
Ending Balance Amount at Sep. 30, 2012	8,808,909	108,354		145,917,968	(1,016,000)	(134,997,680)	(1,203,733)
Stock options exercised, Amount	23,833	$ 45		23,788																																																																																														$ 8,000			$ 8,000
Stock-based compensation	$ 1,241,404			1,241,404
Fractional shares redeemed in reverse stock split		(131)
Preferred stock converted to common stock, shares		275,782	(1,015)
Preferred stock converted to common stock		$ 276	$ (1)	(275)
Issuance and sold of Common Stock																																																																																																																																				1,825,079			1,667,051			239,894			14,262,553			9,900
Ending Balance Shares at Jun. 30, 2013		31,306,318	9,900
Stock options exercised	0
Stock issuances																																																																																																																																			$ 2,678,573	$ 1,826	$ 2,676,747	$ 2,240,936	$ 1,667	$ 2,239,269	$ 986,049	$ 240	$ 985,809	$ 25,459,499	$ 14,263	$ 25,445,236	$ 9,900,000	$ 10	$ 9,899,990
Net income (loss)	$ (17,898,373)					(17,451,105)	(447,268)
Ending Balance Amount at Jun. 30, 2013	33,305,968	$ 123,676	$ 10	187,282,068		$ (152,448,785)	$ (1,651,001)
Stock-based compensation	1,114,375			1,114,375
Subscription reversal, Shares		(267,444)
Subscription payment	$ 16,000				16,000
Subscription reversal		$ (2,674)		$ (997,326)	$ 1,000,000

Consolidated Statement of Stockholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2013	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2009	Sep. 30, 2008	Sep. 30, 2007	Sep. 30, 2006	Sep. 30, 2005	Sep. 30, 2004	Sep. 30, 2003
Issued For Cash At Zero Point Zero One Dollars Per Unit
Common stock & warrants issued for cash, price per unit											$ 0.01
Issued For Cash At Ten Dollar Per Unit
Common stock & warrants issued for cash, price per unit										$ 10.00	$ 10.00
Issued For Marketable Securities At Ten Dollar Per Unit
Common stock & warrants issued for cash, price per unit										10.00
Issued For Cash At Fifteen Dollar Per Unit
Common stock & warrants issued for cash, price per unit										15.00
Issued As Gift For Ten Dollar And Ninety Cents Per Share
Common stock & warrants issued for cash, price per unit										10.90
Issued As Stock Issuance Cost At Fifteen Dollar Per Unit
Common stock & warrants issued for cash, price per unit										15.00
Exercised At Two Dollar Per Share
Exercise of stock options, price per share										2.00
Exercised At Ten Dollar Per Share
Exercise of stock options, price per share									$ 10.00	$ 10.00
Exercised at $15.00 per share
Exercise of stock options, price per share									15.00
Issued to purchase Insert Therapeutics share at $39.80 per share
Common stock issued, par value per share									$ 39.80
Issued at $48.80 per share
Common stock issued, par value per share								$ 48.80
Issued at $38.40 per share
Common stock issued, par value per share								38.40
Issued at $35.00 per share
Common stock issued, par value per share								35.00
Issued at $59.10 per share
Common stock issued, par value per share								59.10
Issued to purchase Calando Pharmaceuticals, Inc. at $51.70 per share
Common stock issued, par value per share								$ 51.70
Issued at $57.80 per share, net
Common stock issued, par value per share							$ 57.80
Issued for purchase of Carbon Nanotechnologies, Inc. at $37.70 per share
Common stock issued, par value per share							$ 37.70
Issued at approximately $18.00 per share, net
Common stock issued, par value per share						$ 18.00
Issued at $27.20 per share to Rice University
Common stock issued, par value per share						27.20
Issued at $28.30 per share to purchase shares of Unidym, Inc.
Common stock issued, par value per share						28.30
Issued at $29.50 per share to purchase MASA Energy, LLC
Common stock issued, par value per share						29.50
Issued at $21.90 per share to Unidym for the acquisition of Nanoconduction
Common stock issued, par value per share						21.90
Issued at $21.80 per share
Common stock issued, par value per share						$ 21.80
Issued at $5.50 per share to Unidym Stockholder in exchange for Unidym's shares
Common stock issued, par value per share					$ 5.50
Issued at $5.20 per share to TEL Ventures in exchange for Unidym's shares
Common stock issued, par value per share					5.20
Issued at $3.00 per share
Common stock issued, par value per share					$ 3.00
Issued at $6.34 per share
Common stock issued, par value per share				$ 6.34
Issued at $13.12 per share
Common stock issued, par value per share				$ 13.12
Issued at $3.80 per share
Common stock issued, par value per share		$ 3.80	$ 3.80
Issued at $3.70 per share
Common stock issued, par value per share		3.70
Issued at $4.00 per share
Common stock issued, par value per share		4.00
Issued at $6.23 per share
Common stock issued, par value per share		6.23
Issued at $5.11 per share
Common stock issued, par value per share		5.11
Issued at $2.76 per share
Common stock issued, par value per share		2.76
Preferred stock issued @ $1,000 per share
Preferred stock issued, par value per share	$ 1,000	$ 1,000
Issued at $2.26 per share
Common stock issued, par value per share	2.26
Issued at $2.12 per share
Common stock issued, par value per share	2.12
Issued at $4.49 per share
Common stock issued, par value per share	4.49
Issued at $1.83 per share
Common stock issued, par value per share	$ 1.83

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		122 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (17,898,373)	$ (16,509,974)	$ (171,551,378)
Net (income) loss attributable to noncontrolling interests	447,268	697,727	19,266,553
NET LOSS ATTRIBUTABLE TO ARROWHEAD	(17,451,105)	(15,812,247)	(152,284,825)
(Income) loss from discontinued operations	354	25	42,838,408
Realized and unrealized (gain) loss on investments		58,091	(762,954)
Charge for bad debt allowance			2,497,300
(Gain) loss from sale of subsidiary			(306,344)
(Gain) loss on purchase of Roche Madison		(1,576,107)	(1,576,107)
(Gain) loss on disposal of fixed assets	76,388	909,761	1,282,853
Stock issued for professional services			741,632
Change in value of derivatives	(215,620)	(226,339)	(3,497,024)
Purchased in-process research and development			15,851,555
Stock-based compensation	1,114,375	837,188	14,695,843
Depreciation and amortization	1,352,448	1,301,806	8,761,734
Amortization (accretion) of note discounts, net	82,341	(20,633)	83,793
Gain on sale of stock in subsidiary			(2,292,800)
Noncash impairment expense	2,315,721	1,455,775	3,958,496
Equity in income (loss) of unconsolidated affiliates		205,361	963,407
Noncontrolling interest	(447,268)	(697,727)	(19,266,553)
Changes in operating assets and liabilities:
Receivables	9,375	169,150	109,415
Other receivables	1,080	1,173,523	(2,542,062)
Prepaid expenses	(441,373)	(152,782)	(922,472)
Other current assets	(1,813)	(30,286)	(165,568)
Accounts payable	183,959	408,263	682,269
Accrued expenses	95,132	514,117	816,041
Other liabilities	(313,354)	730,771	816,807
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATIONS	(13,639,360)	(10,752,290)	(89,517,156)
CASH FLOWS FROM INVESTING ACTIVITIES OF CONTINUING OPERATIONS:
Purchase of property and equipment	(191,656)	(392,799)	(4,236,965)
Proceeds from sale of investments		509,009	3,313,609
Proceeds from sale of fixed assets	(89,505)	25,037	522,192
Purchase of marketable securities	(4,058,003)		(22,633,918)
Proceeds from sale of marketable securities	1,160,181		20,048,446
Cash transferred in acquisitions/divestitures		121,033	(1,579,365)
Purchase of MASA Energy, LLC			(250,000)
Minority equity investment			(2,000,000)
Cash paid for interest in Insert			(10,150,000)
Cash obtained from interest in Insert			10,529,594
Proceeds from sale of subsidiaries			359,375
Payment for patents			(303,440)
Restricted cash			50,773
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS	(2,999,973)	262,280	(6,329,699)
CASH FLOWS FROM FINANCING ACTIVITIES OF CONTINUING OPERATIONS:
Principal payments on capital leases	(160,495)	(143,905)	(357,101)
Proceeds from issuance of common stock and warrants, net	42,448,824	5,401,392	148,701,835
Proceeds from issuance of Calando debt			2,516,467
Proceeds from sale of stock in subsidiary		8,000	20,902,100
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS	42,288,329	5,265,487	171,763,301
Cash flows from discontinued operations:
Operating cash flows	(354)	(225)	(46,004,141)
Investing cash flows			790,625
Financing cash flows			(1,677,000)
Net cash provided by (used in) discontinued operations:	(354)	(225)	(46,890,516)
NET INCREASE (DECREASE) IN CASH	25,648,642	(5,224,748)	29,025,930
CASH AT BEGINNING OF PERIOD	3,377,288	7,507,389
CASH AT END OF PERIOD	29,025,930	2,282,641	29,025,930
Supplementary disclosures:
Interest paid	$ 32,139	$ 34,758	312,827
Taxes paid			$ 742,500

Consolidated Statements of Cash Flows (Parenthetical) - USD ($)	1 Months Ended
	Apr. 30, 2012	Oct. 21, 2011	Sep. 30, 2010	Mar. 31, 2010	Feb. 28, 2010	Nov. 30, 2009	Sep. 30, 2009	Sep. 28, 2009	Sep. 22, 2009	Jun. 25, 2009	Jun. 11, 2009	Aug. 08, 2008	Apr. 29, 2008	Apr. 23, 2008	Apr. 20, 2007	Mar. 31, 2006	Mar. 23, 2005
Warrants exercised				24,788
Stock issued against warrants				12,870
Roche
Shares exchanged as part of acquisition		1,288,158
Issue of promissory note to Roche		$ 50,000
Alvos acquisition
Shares exchanged as part of acquisition	315,457
Series E Preferred Stock
Common stock, shares issued															143,122
Common stock value															$ 5,400,000
Insert Therapeutics, Inc
Purchase of common shares																	7,375,000
Common stock, shares issued																	50,226
Common stock value																	$ 2,000,000
Calando Pharmaceuticals, Inc.
Purchase of common shares					200,000		2,850,000									964,000
Common stock, shares issued					8,000		114,000									20,838
Common stock value							$ 706,800									$ 1,077,333
Value of common stock purchased																1,928,000
Stock purchased by cash					$ 60,000											$ 850,667
Warrants issued					2,400		24,000
Warrants purchased							600,000
Common stock exercise value					$ 5.00
Calando Pharmaceuticals, Inc. \| Series A Preferred Stock
Purchase of common shares			1,562.5
Warrants issued			390,625
Common stock exercise value			$ 5.00
Unidym, Inc.
Purchase of common shares														200,000
Common stock, shares issued								64,227				11,411		7,054
Common stock value								$ 398,209				$ 250,000
Stock purchased by cash														$ 200,000
Unidym, Inc. \| Series A Preferred Stock
Purchase of common shares								5,574
Common stock, shares issued									9,149		132,462
Common stock value									$ 46,662		$ 688,802
Unidym, Inc. \| Series C Preferred Stock
Purchase of common shares								636,699
Common stock, shares issued						15,317				194,444
Common stock value						$ 47,485				$ 972,222
Unidym, Inc. \| Series C One Preferred Stock
Common stock, shares issued							27,777
Common stock value							$ 186,111
MASA Energy LLC
Common stock, shares issued													10,504
Common stock value													$ 310,000
Value of common stock purchased													560,000
Stock purchased by cash													$ 250,000

Organization and Basis of Presentation

9 Months Ended

Jun. 30, 2013

Organization and Basis of Presentation

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

Nature of Business

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference (RNAi) mechanism that efficiently and specifically silence target genes. Arrowhead technologies also enable partners to create peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes programs in chronic hepatitis B virus, obesity, and cancer.

Financing and Liquidity

The Company has historically financed its operations through the sale of equity securities of Arrowhead or its Subsidiaries. Development activities have required significant capital investment since the Company’s inception and we expect our current operations to continue to require cash investment to continue development.

At June 30, 2013, the Company had $33.1 million in cash, including cash invested in short term investments, to fund operations. During the nine months ended June 30, 2013, the Company’s cash position increased $25.6 million. During the nine months ended June 30, 2013, the Company received $42.4 million from the issuance of equity, net of fees. Other cash collections were $1.6 million. The Company had cash outflow of $14.0 million related to its continuing operating activities.

In September 2011, the Company entered into an equity line facility whereby it has the ability to draw capital up to $15 million, subject to certain provisions, including maintaining a minimum stock price of $2.00 per share. During fiscal 2012, the Company drew $1 million from this facility. During fiscal 2013, the Company has not made any draws on this facility.

In December 2012, the Company sold 1.8 million units at a price of $2.26 per unit in a public offering. Each unit consisted of one share of Common Stock and a warrant to purchase 0.5 share of Common Stock. The exercise price of these warrants was $1.83 as of June 30, 2013. Proceeds net of expenses from the offering were $3.8 million.

In January 2013, the Company sold 1.7 million units at a price of $2.12 per unit in a public offering. Each unit consisted of one share of Common Stock and a warrant to purchase 0.5 share of Common Stock. The exercise price of these warrants was $1.83 as of June 30, 2013. Proceeds net of expenses from the offering were $3.3 million.

In May 2013, the Company sold 14.3 million shares of Arrowhead common stock at a price of $1.83 per share, and 9,900 shares of Arrowhead series B convertible preferred stock at a price of $1,000 per share. The series B preferred stock is convertible into common stock at a conversion price of $1.83. Proceeds, net of expenses from the offering, were $35.4 million.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. The September 30, 2012 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2012.

The consolidated financial statements of the Company include the accounts of Arrowhead and its wholly-owned and majority-owned Subsidiaries. Prior to April 2008, Arrowhead’s Subsidiaries included Insert Therapeutics, Inc. (“Insert”), which was merged with Calando in April 2008. The merged entity is majority-owned by Arrowhead and continues to operate under the name of Calando. Arrowhead sold its interests in Unidym and Tego in 2011 and 2009, respectively. Unidym and Tego results are included in the Income (Loss) from Discontinued Operations. Income (Loss) from Discontinued Operations also includes Aonex Technologies, Inc. (“Aonex”), sold in 2008 and Nanotechnica, Inc. (“Nanotechnica”), dissolved in 2005. All significant intercompany accounts and transactions are eliminated in consolidation, and noncontrolling interests are accounted for in the Company’s financial statements. Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.

Investments

The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments – Debt and Equity Securities. This statement requires certain securities to be classified into three categories:

Held-to-maturity – Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost.

Trading Securities – Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings.

Available-for-Sale – Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity.

The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At June 30, 2013, the Company classified all of its investments as held-to-maturity.

Held-to-maturity investments are measured and recorded at amortized cost on the Company’s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary.

As of June 30, 2013, all short-term investments were comprised of corporate bonds with maturity dates of less than one year. The amortized cost of such bonds was $4,058,003. Gross unrealized losses were $17,208; there were no gross unrealized gains. The total fair value of the short-term investments was $4,040,795.

As of September 30, 2012, short-term investments of $106,500 were comprised of equity securities of Wisepower as a result of our disposition of Unidym, such investment has been impaired and its carrying value has been reduced to zero.

See further information regarding fair market value of marketable debt securities in footnote 10 – Fair Value Measurements & Derivative Instruments, such fair market data is obtained from independent pricing services.

Reverse Stock Split

On November 17, 2011, the Company effected a 1 for 10 reverse stock split. As a result of the reverse stock split, each ten shares of the Company’s Common Stock issued and outstanding immediately prior to the reverse stock split were combined into one share of Common Stock. Also, as a result of the reverse stock split, the per share exercise price, and the number of shares of Common Stock underlying Company stock options, warrants, and any Common Stock based equity grants outstanding immediately prior to the reverse stock split was proportionally adjusted, based on the one-for-ten split ratio, in accordance with the terms of such options, warrants or other Common Stock based equity grants. Stockholders received a cash payment in lieu of any resulting fractional shares. All share and per share amounts in these financial statements have been retrospectively adjusted to reflect the reverse stock split. Unless otherwise noted, all impacted information has been retroactively adjusted to reflect this reverse stock split.

Recently Issued Accounting Standards

In July 2012, the FASB issued ASU 2012-02, Testing Indefinite-Lived Intangible Assets for Impairment, which amended the guidance in ASU 2011-08 to simplify the testing of indefinite-lived intangible assets other than goodwill for impairment. ASU 2012-02 becomes effective for annual and interim impairment tests performed for fiscal years beginning on or after September 15, 2012 and earlier adoption is permitted. We adopted this standard in the third quarter of fiscal year 2012. We believe adoption did not have a material effect on our financial statements.

In September 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2011-08, Intangibles – Goodwill and Other (Topic 350) – Testing Goodwill for Impairment (ASU 2011-08), to allow entities to use a qualitative approach to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If after performing the qualitative assessment an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step goodwill impairment test is unnecessary. However, if an entity concludes otherwise, then it is required to perform the first step of the two-step goodwill impairment test. ASU 2011-08 is effective for us in fiscal 2013 and earlier adoption is permitted. The adoption of ASU 2011-08 is not anticipated to impact on our financial position, results of operations or cash flows.

In May 2011, the Financial Accounting Standards Board (“FASB”) issued ASU 2011-04, Fair Value Measurement (“ASU 2011-04”), which amended ASC 820, Fair Value Measurements (“ASC 820”), providing a consistent definition and measurement of fair value, as well as similar disclosure requirements between U.S. GAAP and International Financial Reporting Standards. ASU 2011-04 changes certain fair value measurement principles, clarifies the application of existing fair value measurement and expands the disclosure requirements. ASU 2011-04 was effective for us beginning January 1, 2012. The adoption of ASU 2011-04 did not have a material effect on our consolidated financial statements or disclosures.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

Note Receivable

9 Months Ended

Jun. 30, 2013

Note Receivable

NOTE 2. NOTE RECEIVABLE

As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a Note Receivable from Wisepower (the “Wisepower Note”) in the face amount of $2.5 million. On January 24, 2013, the Company entered into an agreement to sell the Wisepower Note. As consideration for selling the Wisepower Note the Company received 1,570,000 shares of Wisepower stock, (the “First Tranche”). Per the terms of the agreement, the Company was entitled to receive additional consideration (the “Second Tranche”) based on the proceeds realized from the First Tranche, at which time the Company would deliver the Wisepower Note to the Purchaser.

As of June 30, 2013, the Company sold 1,170,000 shares of Wisepower from the First Tranche, and realized approximately $1.2 million in proceeds prior to a trading suspension of Wisepower stock on March 22, 2013. On July 26, 2013, the trading of Wisepower stock resumed, and the company sold the remaining shares from the First Tranche, and realized approximately $260,000. It is unclear when or if the Company will receive the Second Tranche. The Company recorded the $1.2 million proceeds realized from the First Tranche, as of June 30, 2013, against the $2.5 million value of the Wisepower Note, and has recorded a reserve for the uncollectible portion of the Wisepower Note. As of June 30, 2013, the receivable was recorded at $260,000, which was collected in July 2013.The Company is pursuing its rights under the applicable agreements.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5162-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5074-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 13
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3, 4
-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 9

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

+ Details

Acquisitions

9 Months Ended

Jun. 30, 2013

Acquisitions

NOTE 3. ACQUISITIONS

Roche Madison

On October 21, 2011, the Company entered into a Stock and Asset Purchase Agreement (the “RNAi Purchase Agreement”) with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd (collectively, “Roche”), pursuant to which the Company purchased from Roche (i) all of the outstanding common stock of Roche Madison Inc. (“Roche Madison”) and (ii) the intellectual property rights then held by Roche related to its RNAi business and identified in the RNAi Purchase Agreement (the “Transaction”). In consideration for the purchase of Roche Madison and the Roche RNAi assets, the Company issued to Roche a promissory note with a principal value of $50,000 and 1,141,596 shares of Common Stock.The acquisition provided technology, particularly related to RNAi delivery, and a state-of-the-art lab facility.

Pursuant to the RNAi Purchase Agreement, Roche has a right of first negotiation on certain product candidates developed by the Company and its affiliates relating to the purchased assets. If the Company proposes to out-license or enters into substantive negotiations to out-license, any Clinical Candidate or Existing Candidate (as such terms are defined in the RNAi Purchase Agreement), the Company must give notice of the Candidate it proposes to out-license and negotiate exclusively and in good faith with Roche for 90 days regarding the applicable out-license. This right of first negotiation applies to all Existing Candidates (as defined in the RNAi Purchase Agreement) and the first five Clinical Candidates for which the Company delivers notice to Roche and subsequently enters into an out-license.

In addition to the consideration paid by the Company as per the closing terms, the Company is obligated to make certain royalty and milestone payments to Roche upon the occurrence of certain events. For certain product candidates that are developed by the Company or its affiliates and that are covered by a valid claim by the patent rights transferred in the Transaction for which the Company and Roche do not enter into a licensing arrangement, the Company will be obligated to pay a 3% royalty on Net Sales (as defined in the RNAi Purchase Agreement), provided that the royalty rate may be reduced or offset in certain circumstances. The obligation to pay royalties on such candidates will last until the later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate.

The Company will also be obligated to make cash payments to Roche upon the achievement of various milestones, including the first regulatory approval of an Existing Candidate in certain jurisdictions and upon certain annual sales milestones for Existing Candidates that may receive regulatory approval. The potential payments range from $2,500,000 to $6,000,000 per milestone. Based on the Company’s estimate of future payments, a net present value of $84,935 was calculated as contingent consideration, and is recorded as a part of other noncurrent liabilities.

The following table summarizes the estimated fair values at the date of acquisition:

Current assets	$	432,709
Property and equipment		7,215,206
Intangible assets		1,174,935
Other noncurrent assets		6,264
Current liabilities		(414,122	)
Noncurrent liabilities		(1,570,072	)
Gain on purchase		(1,576,106	)
Total purchase consideration	$	5,268,814

The purchase consideration was composed of the following:

Promissory note due Roche	$	50,000
Contingent consideration		84,935
Shares issued to Roche		5,133,879
Total purchase consideration	$	5,268,814

We estimated the fair value of the assets and liabilities acquired through various valuation techniques including a market approach and an income approach. Because the net identifiable tangible and intangible assets and liabilities were in excess of the purchase price, a gain on the purchase of $1.6 million was recorded. The most significant assets capitalized were research equipment and certain in-process research and development. We believe that we were able to acquire these assets at a reasonable purchase price and generate a gain on the transaction due in part from the seller’s desire to exit the relatively early stage of the RNAi business, as compared to the seller’s other business operations, as well as the seller’s desire to dispose of certain on-going costs associated with the facility, primarily lease costs and personnel costs, which were synergistic to the Company’s strategy to establish a research facility to advance development efforts for its drug product candidates.

Alvos Therapeutics

On April 5, 2012, the Company entered into a Stock Purchase Agreement to purchase all of the outstanding shares of Alvos Therapeutics, Inc., (“Alvos”), a privately held company that licensed a large platform of proprietary human-derived Homing Peptides, and the method for their discovery, from MD Anderson Cancer Center. In conjunction with the acquisition, Arrowhead hired one employee from Alvos, and retained one employee on a consulting basis. In exchange for all of the outstanding shares of Alvos, Arrowhead issued an upfront payment of 315,457 shares of Common Stock. The former Alvos stockholders are also eligible to receive additional issuances of stock valued at up to $23.5 million at the time of issuance based on the future achievement of clinical, regulatory and sales milestones. Based on the Company’s estimate of future payments, a net present value of $88,686 was calculated as contingent consideration, and is recorded as a part of other noncurrent liabilities. The Alvos acquisition provided key technology in targeted therapeutics.

The following table summarizes the estimated fair values at the date of acquisition:

Current assets	$	29,332
In-process R&D		2,172,387
Current liabilities		(113,033	)
Total purchase consideration	$	2,088,686

The purchase consideration was comprised of shares of Arrowhead Common Stock issued to the former shareholders of Alvos Therapeutics, Inc.

Shares issued		315,457
Price per share	$	6.34
Share consideration	$	2,000,000
Contingent consideration	$	88,686
Total purchase consideration	$	2,088,686

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7659399&loc=d3e1383-128463

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 88-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph F4
-Subparagraph e
-Appendix F

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51, 52
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 67-73
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Intangible Assets

9 Months Ended

Jun. 30, 2013

Intangible Assets

NOTE 4. INTANGIBLE ASSETS

Intangible assets consist of in-process research and development (IPR&D) not subject to amortization, and patents and other intangible assets subject to amortization, which were capitalized as a part of a business combination.

IPR&D represents projects that have not yet received regulatory approval and are classified as indefinite assets until the successful completion or the abandonment of the associated R&D efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in one or more jurisdictions which, individually or combined, are expected to generate a significant portion of the total revenue expected to be earned by an IPR&D project. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&D and begin amortization. If the associated R&D effort is abandoned the related IPR&D assets would be written off and we would record an impairment loss.

Intangible assets subject to amortization include license agreements and patents capitalized as part of a business combination.

The license agreements are being amortized over the estimated life remaining at the time of acquisition, which was four years. Patents were amortized over a period of three years to twenty years. The weighted average original amortization period is twelve years. Patents have been fully amortized or impaired. Amortization of license agreements is expected to be approximately $14,000 for the balance of fiscal year 2013, and $55,000 for fiscal years 2014 and 2015, $13,000 in 2016, $0 in 2017 and thereafter.

We review amounts capitalized as in-process research and development for impairment at least annually in the fourth quarter, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In the event the carrying value of the assets is not expected to be recovered, the assets are written down to their estimated fair values. We continue to test our indefinite-lived IPR&D assets for potential impairment until the projects are completed or abandoned. During the quarter ended June 30, 2013, the Company recorded an impairment charge relating to patents that were licensed from the California Institute of Technology (the “License”), and had been capitalized. The license agreement was terminated, and it was determined that the value of the capitalized patents had been impaired. Accordingly, the Company recorded an impairment of $1.3 million during the quarter ended June 30, 2013, and is reflected in its operating expenses in its Statement of Operations.

The below table provides details of our intangible asset balances:

	Intangible assets not subject to amortization
Balance at September 30, 2011	$	—	$	1,731,211		$	1,731,211
Additions – Madison acquisition		944,935		230,000			1,174,935
Additions – Alvos acquisition		2,172,387		—			2,172,387
Amortization		—		(293,964	)		(293,964	)
Balance at September 30, 2012	$	3,117,322	$	1,667.247		$	4,784,569
Amortization		0		(222,345	)		(222,345	)
Impairment		—		(1,308,047	)		(1,308,047	)
Balance at June 30, 2013	$	3,117,322	$	136,855		$	3,254,177

Investment in Subsidiaries

9 Months Ended

Jun. 30, 2013

Investment in Subsidiaries

NOTE 5. INVESTMENT IN SUBSIDIARIES

In addition to 100% ownership interest in Arrowhead Madison, Inc. and Alvos Therapeutics, Inc., Arrowhead also maintains majority ownership in Calando Pharmaceuticals, Ablaris Therapeutics, Inc., and a minority investment in Leonardo Biosystems, Inc.

Calando Pharmaceuticals, Inc.

Calando is a clinical stage RNAi therapeutics company. On April 17, 2008, Calando merged with and into Insert, with Insert as the surviving company.

In January 2011, Arrowhead invested $9.1 million, through a cash investment of $1.0 million and the conversion of $8.1 million intercompany debt, acquiring newly issued Calando Series B and Series C preferred stock.

As of June 30, 2013, Calando owed to Arrowhead $3.9 million under a series of 8% simple interest notes and advances. It is expected that these loans will either be repaid or converted to equity in the future. The balance of the notes and advances is eliminated in consolidation.

As of June 30, 2013, Arrowhead owned 79% of the outstanding shares of Calando and 76% on a fully diluted basis.

Ablaris Therapeutics, Inc.

Ablaris was formed and began operations in the first quarter of fiscal 2011, based on the license of anti-obesity technology developed at the MD Anderson Cancer Center at the University of Texas. During the year ended September 30, 2011, Ablaris raised $2.9 million in cash, of which $1.3 million was invested by Arrowhead and $1.6 million was invested by outside investors, through the issuance of Ablaris Series A Preferred stock. As of June 30, 2013, Ablaris owed to Arrowhead $1.3 million from cash advances. It is expected that these advances will either be repaid or converted to equity in the future. The balance of the advances is eliminated in consolidation.

As of June 30, 2013, Arrowhead owned 64% of the outstanding shares of Ablaris and 64% on a fully diluted basis.

Leonardo Biosystems, Inc.

Leonardo is developing a drug-delivery platform technology based on novel methods of designing porous silicon microparticles that selectively accumulate in tumor vasculature. Arrowhead accounts for its investment in Leonardo using the cost method of accounting. As of June 30, 2013, Leonardo owed to Arrowhead $858,000, included in other receivables. The Company has provided a full reserve against the receivable from Leonardo. As of June 30, 2013, Arrowhead’s ownership interest in Leonardo was 3%.

- Definition

The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.

+ References + Details

Notes Payable

9 Months Ended

Jun. 30, 2013

Notes Payable

NOTE 6. NOTES PAYABLE

In 2008 and 2009, Calando entered into Unsecured Convertible Promissory Note Agreements (“Notes”) for $2.5 million with accredited investors and Arrowhead, which invested $800,000 in the Notes offering.Except for one Note in the principal amount of $500,000, all Notes and accrued interest were converted into a total of 2,950 shares of Calando Series A Preferred Stock in 2009. The remaining Note was renegotiated and extended until November 26, 2013. The terms of the new note include a 10% interest rate and require two times principal payment upon certain events as defined in the note and at maturity. At June 30, 2013, the Note is reflected on the balance sheet at the maturity amount of $1,000,000 less a discount of $74,351.

Also, as part of the acquisition of Roche Madison, Inc. in October 2011, the Company recorded a note payable of $50,000, which is due October 17, 2014 and is reflected in long-term liabilities on the Company’s balance sheet.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Stockholders' Equity

9 Months Ended

Jun. 30, 2013

Stockholders' Equity

NOTE 7. STOCKHOLDERS’ EQUITY

At June 30, 2013, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001, and 5,000,000 shares of Preferred Stock, par value $0.001.

At June 30, 2013, 31,306,318 shares of Common Stock were outstanding, and 9,900 shares of Preferred Stock were outstanding. At June 30, 2013, 3,369,960 shares were reserved for issuance upon exercise of outstanding stock options. An additional 6,055,535 shares were reserved for the issuance of shares related to warrants outstanding at June 30, 2013.

On September 30, 2011, the Company sold 1,191,473 shares of Common Stock at a price of $3.80 per share. Cash proceeds received in fiscal 2011 were $4.5 million. On October 4, 2011, the Company completed a second closing of the offering in which the Company sold 138,158 shares of Common Stock at a price of $3.80 per share. Cash proceeds were $525,000.

In October 2011, the Company entered into Subscription Agreements with certain accredited investors (the “Series A Purchasers”), pursuant to which the Company issued and sold an aggregate of 1,015 shares of Series A Preferred Convertible Stock, $0.001 par value per share, at a purchase price of $1,000 per share. The aggregate purchase price paid for the shares of Series A Preferred was $1,015,000. On February 16, 2012, upon approval by the Company’s shareholders, 1,015 shares of Arrowhead Series A Preferred Convertible Stock, $0.001 par value per share, were converted to 275,782 shares of Common Stock.

On October 21, 2011, the Company entered into a Subscription Agreement with an accredited investor, pursuant to which the Company issued and sold an aggregate of 675,000 shares of Common Stock, $0.001 par value per share, at a purchase price of $3.70 per share. The aggregate purchase price paid by the purchaser for the shares of Common Stock was $2,497,500.

On August 10, 2012, the Company sold 2,260,869 units at a price of $2.76 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.75 shares of common stock at an exercise price of $3.25. Gross proceeds from the offering were $6.2 million excluding offering fees and expenses.

In December 2012, the Company sold 1,825,079 units at a price of $2.26 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock. Gross proceeds from the offering were $4.1 million excluding offering fees and expenses. The exercise price of these warrants was $1.83 as of June 30, 2013.

In January 2013, the Company sold 1,667,051 units at a price of $2.12 per unit. Each unit consisted of one share of common stock and a warrant to purchase 0.5 shares of common stock. Gross proceeds from the offering were $3.5 million excluding offering fees and expenses. The exercise price of these warrants was $1.83 as of June 30, 2013.

In May 2013, the Company sold 14.3 million shares of Arrowhead common stock at a price of $1.83 per share and 9,900 shares of Arrowhead series B convertible preferred stock at a price of $1,000 per share. The series B preferred stock is convertible into common stock at a conversion price of $1.83. Gross proceeds were $36 million. No warrants were issued in the May 2013 financing.

The following table summarizes information about warrants outstanding at June 30, 2013:

Exercise prices			Remaining Life in Years
$	70.60	94,897	3.9
$	20.00	386,400	0.1
$	5.00	1,155,023	1.4
$	5.09	461,024	1.4
$	1.38	322,150	2.5
$	4.16	1,000	3.5
$	3.25	1,695,654	3.1
$	1.83	987,543	4.5
$	2.83	79,013	3.1
$	1.83	833,530	4.6
$	2.65	39,301	3.1
Total warrants outstanding		6,055,535

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Leases

9 Months Ended

Jun. 30, 2013

Leases

NOTE 8. LEASES

The Company’s research facility in Madison, Wisconsin is leased through February 28, 2019. Monthly rental expense is approximately $22,000. Other monthly rental expenses include common area maintenance and real estate taxes totaling approximately $13,000 per month. Utilities costs are approximately $16,000 per month. Including monthly payments recorded under a capital lease of approximately $21,000, total monthly costs are approximately $72,000 per month. The Company’s corporate headquarters are located in Pasadena, California; Rental expense is approximately $13,000 per month.

Facility and equipment rent expense, related to continuing operations, for the nine months ended June 30, 2013 and 2012 was $407,000 and $345,000, respectively. From inception to date through June 30, 2013, rent expense was $4,532,000.

As of June 30, 2013, future minimum lease payments due in fiscal years under capitalized leases are as follows:

2013	$	64,211
2014		256,846
2015		256,846
2016		256,846
2017		256,846
2018		256,846
2019 and thereafter		107,020
Less interest		(118,697	)
Principal		1,336,764
Less current portion		(219,690	)
Noncurrent portion	$	1,117,074

As of June 30, 2013, future minimum lease payments due in fiscal years under operating leases are as follows:

2013	$	94,661
2014		434,229
2015		445,921
2016		457,961
2017		470,154
2018		359,370
2019 and thereafter		125,415
Total	$	2,387,711

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References + Details

Stock-Based Compensation

9 Months Ended

Jun. 30, 2013

Stock-Based Compensation

NOTE 9. STOCK-BASED COMPENSATION

Arrowhead has two plans that provide for equity-based compensation. Under the 2000 Stock Option Plan, 153,200 shares of Arrowhead’s Common Stock are reserved for issuance upon exercise of non-qualified stock options. No further grants can be made under the 2000 Stock Option Plan. Under the 2004 Equity Incentive Plan, 3,000,000 shares of Common Stock are authorized for issuance, of which 510,166 shares are available as of June 30, 2013 for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards, by the Compensation Committee of the Board of Directors, to employees, consultants and others. 2,965,860 shares of Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards, by the Compensation Committee of the Board of Directors, to employees, consultants and others. As of June 30, 2013, there were options granted and outstanding to purchase 152,900 and 2,455,694 shares of Common Stock under the 2000 Stock Option Plan and the 2004 Equity Incentive Plan, respectively, and 251,200 options outstanding that were issued outside of equity incentive plans, as inducement options.

During the nine months ended June 30, 2013, 949,000 options were granted under the 2004 Equity Incentive Plan.

The following tables summarize information about stock options under the 2000 Stock Option Plan, the 2004 Stock Option Plan and as inducement options outside of an equity incentive plan:

			Weighted- Average Exercise Price Per Share			Aggregate Intrinsic Value
Balance At September 30, 2011	729,096		$	9.03
Granted	1,229,500			4.40
Cancelled	(42,919	)		11.77
Exercised	(4,883	)		5.20
Balance At September 30, 2012	1,910,794		$	6.01
Granted	949,000			2.03
Cancelled	0			0
Exercised	0			0
Balance At June 30, 2013	2,859,794		$	4.69	8.2 years	$	—
Exercisable At June 30, 2013	1,129,939		$	7.01	6.6 years	$	—

Stock-based compensation expense for the nine months ended June 30, 2013 and 2012 was $1,114,375 and $837,188, respectively. There is no income tax benefit as the Company is currently operating at a loss and an actual income tax benefit may not be realized. The loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.

The fair value of the options granted by Arrowhead during the nine months ended June 30, 2013 and 2012 is estimated at $1,197,588 and $3,505,912, respectively. The aggregate fair value of options granted by Calando during the nine months ended June 30, 2013 and 2012 is estimated at $0 and $33,690, respectively.

The intrinsic value of the options exercised during the nine months ended June 30, 2013 was $0, there were no options exercised during the nine months ended June 30, 2013.

As of June 30, 2013, the pre-tax compensation expense for all unvested stock options at Arrowhead in the amount of approximately $3,775,514 will be recognized in our results of operations over a weighted average period of 2.9 years. As of June 30, 2013, the pre-tax compensation expense for all unvested stock options at Calando in the amount of approximately $39,169 will be recognized in our results of operations over a weighted average period of 2.2 years.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by our stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

The assumptions used to value stock options are as follows:

	Nine months ended June 30,
	2013			2012
Dividend yield		0			—
Risk-free interest rate	0.7% to 1.25%			0.9% to 1.7%
Volatility		69	%	90% to 100%
Expected life (in years)	5.5 to 6.25			5.5 to 6.25
Weighted average grant date fair value per share of options granted	$	1.26		$	3.79

The dividend yield is zero as the Company currently does not pay a dividend.

The risk-free interest rate is based on the U.S. Treasury bond.

Volatility is estimated based on volatility average of the Company’s Common Stock price.

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details

Fair Value Measurements & Derivative Instruments

9 Months Ended

Jun. 30, 2013

Fair Value Measurements & Derivative Instruments

NOTE 10. FAIR VALUE MEASUREMENTS & DERIVATIVE INSTRUMENTS

The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level 1 provides the most reliable measure of fair value while Level 3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows:

Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly.

Level 3—Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management’s best estimate of what market participants would use in valuing the asset or liability at the measurement date.

The following table summarizes fair value measurements at June 30, 2013 and September 30, 2012 for assets and liabilities measured at fair value on a recurring basis:

June 30, 2013:

	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	29,025,930	$	—	$	—	$	29,025,930
Marketable securities (1)	$	4,040,795	$	—	$	—	$	4,040,795
Derivative assets	$	—	$	—	$	—	$	—
Derivative liabilities	$	—	$	—	$	2,335,163	$	2,335,163
Contingent consideration	$	—	$	—	$	173,621	$	173,621

September 30, 2012:

	Level 1		Level 2			Level 3			Total
Cash and cash equivalents	$	3,377,288	$	—	$		—	$		3,377,288
Marketable securities	$	106,500	$	—	$		—	$		106,500
Derivative assets	$	—	$	—	$		250,250	$		250,250
Derivative liabilities	$	—	$	—	$		647,213	$		647,213
Contingent consideration	$	—	$	—	$		173,621	$		173,621

(1) Marketable securities at June 30, 2013 were comprised of investments classified as “held-to-maturity”, and are recorded at amortized cost on the Company’s Consolidated Balance Sheet.

As part of the proceeds from the sale of Unidym in January 2011, Arrowhead received a bond from Wisepower in the face amount of $2.5 million. The bond is convertible to Wisepower common stock at a price of $2.00 per share. The conversion feature is subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the conversion feature on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative asset. The fair value of the conversion feature is estimated at the end of each reporting period and the change in the fair value of the conversion feature is recorded as a nonoperating gain/loss as change in value of derivatives in Company’s Consolidated Statement of Operations. During the quarter ended March 31, 2013, the trading of Wisepower stock was halted. Trading resumed in July 2013, but the trading price is significantly below the conversion price. The Company determined that the probability of realizing value from the conversion feature was remote, and the derivative asset value has been reduced to zero.

During the nine months ended June 30, 2013, the Company recorded a loss from the change in fair value of the derivative asset of $250,250.

The assumptions used in valuing the derivative asset were as follows:

	June 30, 2013		September 30, 2012
Risk free interest rate	NA		0.23	%
Expected life	0 Years		1.3 Years
Dividend yield	none		none
Volatility	72	%	72	%

The following is a reconciliation of the derivative asset:

Value at September 30, 2011	$	161,125
Receipt of instruments		—
Increase in value		89,125
Net settlements		—
Value at September 30, 2012	$	250,250
Receipt of instruments		—
Change in value		(250,250	)
Net settlements		—
Value at June 30, 2013	$	—

As part of an equity financing in June 2010, Arrowhead issued warrants to acquire up to 329,649 shares of Common Stock (the “2010 Warrants”), of which 322,150 warrants were outstanding at June 30, 2013, which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2010 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2010 Warrants, the exercise price of the 2010 Warrants would be reduced to the amount equal to the issuance price of the Common Stock. Similarly, as part of a financing in December 2012, Arrowhead issued warrants to acquire up to 912,543 shares of Common Stock (the “2012 Warrants”) which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2012 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2012 Warrants, the exercise price of the 2012 Warrants would be reduced to the amount equal to the issuance price of the Common Stock. Further, as part of a financing in January 2013, Arrowhead issued warrants to acquire up to 833,530 shares of Common Stock (the “2013 Warrants”) which contain a mechanism to adjust the strike price upon the issuance of certain dilutive equity securities. If during the term of the 2013 Warrants, the Company issues Common Stock at a price lower than the exercise price of the 2013 Warrants, the exercise price of the 2013 Warrants would be reduced to the amount equal to the issuance price of the Common Stock.

As a result of these features, the 2010 Warrants, the 2012 Warrants, and the 2013 Warrants are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the Warrants on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative liability. The fair value of the Warrants is estimated at the end of each reporting period and the change in the fair value of the Warrants is recorded as a nonoperating gain or loss in the Company’s consolidated statement of operations. During the nine months ended June 30, 2013, the Company recorded a non-cash gain from the change in fair value of the derivative liability of $465,869.

The assumptions used in valuing the derivative liabilities were as follows:

2010 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	0.51	%	0.31	%
Expected life	2.5 Years		3.2 Years
Dividend yield	none		none
Volatility	69	%	100	%

2012 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	N/A
Expected life	4.5 Years		N/A
Dividend yield	none		N/A
Volatility	69	%	N/A

2013 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	N/A
Expected life	4.6 Years		N/A
Dividend yield	none		N/A
Volatility	69	%	N/A

The following is a reconciliation of the derivative liability related to these warrants:

Value at September 30, 2011	$	944,980
Issuance of instruments		—
Change in value		(297,767	)
Net settlements		—
Value at September 30, 2012	$	647,213
Issuance of instruments		1,137,896
Issuance of instruments		1,015,923
Change in value		(465,869	)
Net settlements		—
Value at June 30, 2013	$	2,335,163

In conjunction with the financing of Ablaris during the year ended September 30, 2011, Arrowhead sold exchange rights to certain investors whereby the investors have the right to exchange their shares of Ablaris for a prescribed number of shares of Arrowhead Common Stock based upon a predefined ratio. The exchange rights have a seven-year term. During the first year, the exchange right allows the holder to exchange one Ablaris share for 0.06 Arrowhead shares. This ratio declines to 0.04 in the second year, 0.03 in the third year and 0.02 in the fourth year. In the fifth year and beyond the exchange ratio is 0.01. Exchange rights for 675,000 Ablaris shares were sold during the year ended September 30, 2011, and remain outstanding. The exchange rights are subject to derivative accounting as prescribed under ASC 815. Accordingly, the fair value of the exchange rights on the date of issuance was estimated using an option pricing model and recorded on the Company’s consolidated balance sheet as a derivative liability. The fair value of the exchange rights is estimated at the end of each reporting period and the change in the fair value of the exchange rights is recorded as a nonoperating gain or loss in the Company’s Consolidated Statement of Operations. During the nine months ended June 30, 2013, the Company recorded a non-cash gain from the change in fair value of the derivative liability of $9,877.

The assumptions used in valuing the derivative liability were as follows:

	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	0.62	%
Expected life	4.5 Years		5.3 Years
Dividend yield	none		none
Volatility	69	%	100	%

The following is a reconciliation of the derivative liability related to these exchange rights:

Value at September 30, 2010	$	—
Issuance of instruments		100,650
Change in value		(69,758	)
Value at September 30, 2011	$	30,892
Issuance of instruments		—
Change in value		(20,520	)
Net settlements		—
Value at September 30, 2012	$	10,372
Issuance of instruments		—
Change in value		(9,877	)
Net settlements		—
Value at June 30, 2013	$	495

During the year ended September 30, 2012, contingent consideration was recorded upon the acquisitions of Roche Madison, Inc. and Alvos Therapeutics, Inc., totaling $173,621. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. Estimating timing to complete the development, and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations.

There were no changes in contingent consideration fair value.

Value at September 30, 2011	$	—
Purchase price contingent consideration		173,621
Contingent consideration payments		—
Change in fair value of contingent consideration		—
Value at September 30, 2012	$	173,621
Purchase price contingent consideration		—
Contingent consideration payments		—
Change in fair value of contingent consideration		—
Value at June 30, 2013	$	173,621

The carrying amounts of the Company’s other financial instruments, which include accounts receivable, accounts payable, and accrued expenses approximate their respective fair values due to the relatively short-term nature of these instruments. The carrying value of the Company’s debt obligations approximates fair value based on market interest rates.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events

9 Months Ended

Jun. 30, 2013

Subsequent Events

NOTE 11. SUBSEQUENT EVENTS

On August 6, 2013, Calando, a majority-owned subsidiary of the Company, terminated a License Agreement with the California Institute of Technology (the “License”). The License provided Calando with exclusive rights to develop and commercialize therapeutics based on the linear cyclodextrin drug delivery technology invented at Caltech. The drug delivery technology platforms, CyclosertTM and RONDELTM, as well as the drug candidates IT-101 and CALAA-01, were developed based on the licensed technology. Calando was responsible to direct and pay for the prosecution of the patents and patent applications covered by the License and to progress the technology. In conjunction with a previous business acquisition, the patents covered by this license agreement had been capitalized, and had a net book value of $1.3 million at June 30, 2013. Management has determined that the value of the patents was impaired as of June 30, 2013, and the Company recorded an impairment charge of $1.3 million, and is presented as a part of operating expenses in the period ended June 30, 2013.

Organization and Basis of Presentation (Policies)	9 Months Ended
Organization and Basis of Presentation (Policies)	Jun. 30, 2013
Nature of Business	Nature of Business Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference (RNAi) mechanism that efficiently and specifically silence target genes. Arrowhead technologies also enable partners to create peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes programs in chronic hepatitis B virus, obesity, and cancer.
Financing and Liquidity	Financing and Liquidity The Company has historically financed its operations through the sale of equity securities of Arrowhead or its Subsidiaries. Development activities have required significant capital investment since the Company’s inception and we expect our current operations to continue to require cash investment to continue development. At June 30, 2013, the Company had $33.1 million in cash, including cash invested in short term investments, to fund operations. During the nine months ended June 30, 2013, the Company’s cash position increased $25.6 million. During the nine months ended June 30, 2013, the Company received $42.4 million from the issuance of equity, net of fees. Other cash collections were $1.6 million. The Company had cash outflow of $14.0 million related to its continuing operating activities. In September 2011, the Company entered into an equity line facility whereby it has the ability to draw capital up to $15 million, subject to certain provisions, including maintaining a minimum stock price of $2.00 per share. During fiscal 2012, the Company drew $1 million from this facility. During fiscal 2013, the Company has not made any draws on this facility. In December 2012, the Company sold 1.8 million units at a price of $2.26 per unit in a public offering. Each unit consisted of one share of Common Stock and a warrant to purchase 0.5 share of Common Stock. The exercise price of these warrants was $1.83 as of June 30, 2013. Proceeds net of expenses from the offering were $3.8 million. In January 2013, the Company sold 1.7 million units at a price of $2.12 per unit in a public offering. Each unit consisted of one share of Common Stock and a warrant to purchase 0.5 share of Common Stock. The exercise price of these warrants was $1.83 as of June 30, 2013. Proceeds net of expenses from the offering were $3.3 million. In May 2013, the Company sold 14.3 million shares of Arrowhead common stock at a price of $1.83 per share, and 9,900 shares of Arrowhead series B convertible preferred stock at a price of $1,000 per share. The series B preferred stock is convertible into common stock at a conversion price of $1.83. Proceeds, net of expenses from the offering, were $35.4 million.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year. The September 30, 2012 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. This financial information should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2012. The consolidated financial statements of the Company include the accounts of Arrowhead and its wholly-owned and majority-owned Subsidiaries. Prior to April 2008, Arrowhead’s Subsidiaries included Insert Therapeutics, Inc. (“Insert”), which was merged with Calando in April 2008. The merged entity is majority-owned by Arrowhead and continues to operate under the name of Calando. Arrowhead sold its interests in Unidym and Tego in 2011 and 2009, respectively. Unidym and Tego results are included in the Income (Loss) from Discontinued Operations. Income (Loss) from Discontinued Operations also includes Aonex Technologies, Inc. (“Aonex”), sold in 2008 and Nanotechnica, Inc. (“Nanotechnica”), dissolved in 2005. All significant intercompany accounts and transactions are eliminated in consolidation, and noncontrolling interests are accounted for in the Company’s financial statements. Certain reclassifications have been made to prior period financial statements to conform to the current period presentation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager.
Investments	Investments The Company invests excess cash balances in short-term and long-term marketable debt securities. Investments may consist of certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with FASB ASC 320, Investments – Debt and Equity Securities. This statement requires certain securities to be classified into three categories: Held-to-maturity – Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. Trading Securities – Debt and equity securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. Available-for-Sale – Debt and equity securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders’ equity. The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. At June 30, 2013, the Company classified all of its investments as held-to-maturity. Held-to-maturity investments are measured and recorded at amortized cost on the Company’s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. As of June 30, 2013, all short-term investments were comprised of corporate bonds with maturity dates of less than one year. The amortized cost of such bonds was $4,058,003. Gross unrealized losses were $17,208; there were no gross unrealized gains. The total fair value of the short-term investments was $4,040,795. As of September 30, 2012, short-term investments of $106,500 were comprised of equity securities of Wisepower as a result of our disposition of Unidym, such investment has been impaired and its carrying value has been reduced to zero. See further information regarding fair market value of marketable debt securities in footnote 10 – Fair Value Measurements & Derivative Instruments, such fair market data is obtained from independent pricing services.
Reverse Stock Split	Reverse Stock Split On November 17, 2011, the Company effected a 1 for 10 reverse stock split. As a result of the reverse stock split, each ten shares of the Company’s Common Stock issued and outstanding immediately prior to the reverse stock split were combined into one share of Common Stock. Also, as a result of the reverse stock split, the per share exercise price, and the number of shares of Common Stock underlying Company stock options, warrants, and any Common Stock based equity grants outstanding immediately prior to the reverse stock split was proportionally adjusted, based on the one-for-ten split ratio, in accordance with the terms of such options, warrants or other Common Stock based equity grants. Stockholders received a cash payment in lieu of any resulting fractional shares. All share and per share amounts in these financial statements have been retrospectively adjusted to reflect the reverse stock split. Unless otherwise noted, all impacted information has been retroactively adjusted to reflect this reverse stock split.

- Definition

Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.

+ References + Details

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2,12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872867&loc=d3e40691-111596

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 7-18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 2, 12
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10, 11
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Acquisitions (Tables)

9 Months Ended

Jun. 30, 2013

Roche Madison Inc

Summary of Estimated Fair Values at Date of Acquisition

The following table summarizes the estimated fair values at the date of acquisition:

Current assets	$	432,709
Property and equipment		7,215,206
Intangible assets		1,174,935
Other noncurrent assets		6,264
Current liabilities		(414,122	)
Noncurrent liabilities		(1,570,072	)
Gain on purchase		(1,576,106	)
Total purchase consideration	$	5,268,814

Purchase Consideration

The purchase consideration was composed of the following:

Promissory note due Roche	$	50,000
Contingent consideration		84,935
Shares issued to Roche		5,133,879
Total purchase consideration	$	5,268,814

Alvos acquisition

Summary of Estimated Fair Values at Date of Acquisition

The following table summarizes the estimated fair values at the date of acquisition:

Current assets	$	29,332
In-process R&D		2,172,387
Current liabilities		(113,033	)
Total purchase consideration	$	2,088,686

Purchase Consideration

The purchase consideration was comprised of shares of Arrowhead Common Stock issued to the former shareholders of Alvos Therapeutics, Inc.

Shares issued		315,457
Price per share	$	6.34
Share consideration	$	2,000,000
Contingent consideration	$	88,686
Total purchase consideration	$	2,088,686

Intangible Assets (Tables)

9 Months Ended

Jun. 30, 2013

Schedule of Intangible Asset

The below table provides details of our intangible asset balances:

	Intangible assets not subject to amortization
Balance at September 30, 2011	$	—	$	1,731,211		$	1,731,211
Additions – Madison acquisition		944,935		230,000			1,174,935
Additions – Alvos acquisition		2,172,387		—			2,172,387
Amortization		—		(293,964	)		(293,964	)
Balance at September 30, 2012	$	3,117,322	$	1,667.247		$	4,784,569
Amortization		0		(222,345	)		(222,345	)
Impairment		—		(1,308,047	)		(1,308,047	)
Balance at June 30, 2013	$	3,117,322	$	136,855		$	3,254,177

Stockholders' Equity (Tables)

9 Months Ended

Jun. 30, 2013

Summary of Information About Warrants

The following table summarizes information about warrants outstanding at June 30, 2013:

Exercise prices			Remaining Life in Years
$	70.60	94,897	3.9
$	20.00	386,400	0.1
$	5.00	1,155,023	1.4
$	5.09	461,024	1.4
$	1.38	322,150	2.5
$	4.16	1,000	3.5
$	3.25	1,695,654	3.1
$	1.83	987,543	4.5
$	2.83	79,013	3.1
$	1.83	833,530	4.6
$	2.65	39,301	3.1
Total warrants outstanding		6,055,535

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Leases (Tables)

9 Months Ended

Jun. 30, 2013

Future Minimum Lease Payments Under Capitalized Leases

As of June 30, 2013, future minimum lease payments due in fiscal years under capitalized leases are as follows:

2013	$	64,211
2014		256,846
2015		256,846
2016		256,846
2017		256,846
2018		256,846
2019 and thereafter		107,020
Less interest		(118,697	)
Principal		1,336,764
Less current portion		(219,690	)
Noncurrent portion	$	1,117,074

Future Minimum Lease Payments Under Operating Leases

As of June 30, 2013, future minimum lease payments due in fiscal years under operating leases are as follows:

2013	$	94,661
2014		434,229
2015		445,921
2016		457,961
2017		470,154
2018		359,370
2019 and thereafter		125,415
Total	$	2,387,711

Stock-Based Compensation (Tables)

9 Months Ended

Jun. 30, 2013

Summarize Information about Stock Options

The following tables summarize information about stock options under the 2000 Stock Option Plan, the 2004 Stock Option Plan and as inducement options outside of an equity incentive plan:

			Weighted- Average Exercise Price Per Share			Aggregate Intrinsic Value
Balance At September 30, 2011	729,096		$	9.03
Granted	1,229,500			4.40
Cancelled	(42,919	)		11.77
Exercised	(4,883	)		5.20
Balance At September 30, 2012	1,910,794		$	6.01
Granted	949,000			2.03
Cancelled	0			0
Exercised	0			0
Balance At June 30, 2013	2,859,794		$	4.69	8.2 years	$	—
Exercisable At June 30, 2013	1,129,939		$	7.01	6.6 years	$	—

Assumptions Used to Value Stock Options

The assumptions used to value stock options are as follows:

	Nine months ended June 30,
	2013			2012
Dividend yield		0			—
Risk-free interest rate	0.7% to 1.25%			0.9% to 1.7%
Volatility		69	%	90% to 100%
Expected life (in years)	5.5 to 6.25			5.5 to 6.25
Weighted average grant date fair value per share of options granted	$	1.26		$	3.79

Fair Value Measurements & Derivative Instruments (Tables)

9 Months Ended

Jun. 30, 2013

Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes fair value measurements at June 30, 2013 and September 30, 2012 for assets and liabilities measured at fair value on a recurring basis:

June 30, 2013:

	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	29,025,930	$	—	$	—	$	29,025,930
Marketable securities (1)	$	4,040,795	$	—	$	—	$	4,040,795
Derivative assets	$	—	$	—	$	—	$	—
Derivative liabilities	$	—	$	—	$	2,335,163	$	2,335,163
Contingent consideration	$	—	$	—	$	173,621	$	173,621

September 30, 2012:

	Level 1		Level 2			Level 3			Total
Cash and cash equivalents	$	3,377,288	$	—	$		—	$		3,377,288
Marketable securities	$	106,500	$	—	$		—	$		106,500
Derivative assets	$	—	$	—	$		250,250	$		250,250
Derivative liabilities	$	—	$	—	$		647,213	$		647,213
Contingent consideration	$	—	$	—	$		173,621	$		173,621

Assumptions Used in Valuing Derivative Asset

The assumptions used in valuing the derivative asset were as follows:

	June 30, 2013		September 30, 2012
Risk free interest rate	NA		0.23	%
Expected life	0 Years		1.3 Years
Dividend yield	none		none
Volatility	72	%	72	%

Reconciliation of Derivative Asset

The following is a reconciliation of the derivative asset:

Value at September 30, 2011	$	161,125
Receipt of instruments		—
Increase in value		89,125
Net settlements		—
Value at September 30, 2012	$	250,250
Receipt of instruments		—
Change in value		(250,250	)
Net settlements		—
Value at June 30, 2013	$	—

Change in Fair Value of Contingent Consideration Obligations

There were no changes in contingent consideration fair value.

Value at September 30, 2011	$	—
Purchase price contingent consideration		173,621
Contingent consideration payments		—
Change in fair value of contingent consideration		—
Value at September 30, 2012	$	173,621
Purchase price contingent consideration		—
Contingent consideration payments		—
Change in fair value of contingent consideration		—
Value at June 30, 2013	$	173,621

Warrants

Assumptions Used in Valuing Derivative Liabilities

The assumptions used in valuing the derivative liabilities were as follows:

2010 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	0.51	%	0.31	%
Expected life	2.5 Years		3.2 Years
Dividend yield	none		none
Volatility	69	%	100	%

2012 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	N/A
Expected life	4.5 Years		N/A
Dividend yield	none		N/A
Volatility	69	%	N/A

2013 Warrants	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	N/A
Expected life	4.6 Years		N/A
Dividend yield	none		N/A
Volatility	69	%	N/A

Reconciliation of Derivative Liability

The following is a reconciliation of the derivative liability related to these warrants:

Value at September 30, 2011	$	944,980
Issuance of instruments		—
Change in value		(297,767	)
Net settlements		—
Value at September 30, 2012	$	647,213
Issuance of instruments		1,137,896
Issuance of instruments		1,015,923
Change in value		(465,869	)
Net settlements		—
Value at June 30, 2013	$	2,335,163

Exchange rights

Assumptions Used in Valuing Derivative Liabilities

The assumptions used in valuing the derivative liability were as follows:

	June 30, 2013		September 30, 2012
Risk free interest rate	1.41	%	0.62	%
Expected life	4.5 Years		5.3 Years
Dividend yield	none		none
Volatility	69	%	100	%

Reconciliation of Derivative Liability

The following is a reconciliation of the derivative liability related to these exchange rights:

Value at September 30, 2010	$	—
Issuance of instruments		100,650
Change in value		(69,758	)
Value at September 30, 2011	$	30,892
Issuance of instruments		—
Change in value		(20,520	)
Net settlements		—
Value at September 30, 2012	$	10,372
Issuance of instruments		—
Change in value		(9,877	)
Net settlements		—
Value at June 30, 2013	$	495

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Organization and Basis of Presentation - Additional Information (Detail)	1 Months Ended				3 Months Ended	9 Months Ended		12 Months Ended	122 Months Ended
	May 31, 2013 USD ($) $ / shares shares	Jan. 31, 2013 USD ($) $ / shares $ / Warrant shares	Dec. 31, 2012 USD ($) $ / shares shares	Aug. 10, 2012 USD ($) $ / shares shares	Jun. 30, 2013 USD ($) $ / Warrant shares	Jun. 30, 2013 USD ($) $ / Warrant	Jun. 30, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2013 USD ($) $ / Warrant	Sep. 30, 2011 USD ($) $ / shares
Schedule Of Investments [Line Items]
Cash for fund operations					$ 29,025,930	$ 29,025,930	$ 2,282,641	$ 3,377,288	$ 29,025,930	$ 7,507,389
Net increase decrease in cash						25,648,642	(5,224,748)		29,025,930
Cash from issuance of equity	$ 36,000,000	$ 3,300,000	$ 3,800,000		$ 1,200,000	42,400,000
Other cash collections						1,600,000
Cash outflow from continuing operations						$ (13,639,360)	(10,752,290)		$ (89,517,156)
Drawing Limit under Equity Line Facility										$ 15,000,000
Minimum stock price required to maintain under equity line facility \| $ / shares										$ 2.00
Proceeds from equity line facility								1,000,000
Shares issued under public offering \| shares		1,667,051	1,800,000.0		1,170,000
Shares issued under public offering, price per share \| $ / shares		$ 2.12	$ 2.26
Unit sold, description		Each unit consisted of one share of Common Stock and a warrant to purchase	Each unit consisted of one share of Common Stock and a warrant to purchase
Warrant to purchase share of Common Stock \| shares		0.5	0.5
Exercise price of warrant \| $ / Warrant		1.83			1.83	1.83			1.83
Issuance and sold of stock \| shares	14,300,000.0			2,260,869
Sale of stock, price per share \| $ / shares	$ 1.83			$ 2.76
Proceeds from issuance of common stock and warrants, net	$ 35,400,000	$ 3,500,000		$ 6,200,000		$ 42,448,824	$ 5,401,392		$ 148,701,835
Reverse stock split						0.1
Short term investments					$ 4,058,003	$ 4,058,003		$ 106,500	4,058,003
Gross unrealized losses						17,208
Fair value of investments					$ 4,040,795	4,040,795			$ 4,040,795
Gross unrealized gains						$ 0
Series B convertible preferred stock
Schedule Of Investments [Line Items]
Issuance and sold of stock \| shares	9,900
Sale of stock, price per share \| $ / shares	$ 1,000
Conversion price \| $ / shares	$ 1.83
Warrants Issued
Schedule Of Investments [Line Items]
Exercise price of warrant \| $ / Warrant					1.83	1.83			1.83

Note Receivable - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	May 31, 2013	Jan. 31, 2013	Dec. 31, 2012	Jun. 30, 2013	Jun. 30, 2013	Jan. 24, 2013	Jan. 31, 2011
Accounts Notes And Loans Receivable [Line Items]
Note receivable realized amount				$ 260,000	$ 260,000
Shares issued under public offering		1,667,051	1,800,000.0	1,170,000
Shares issued under public offering, value	$ 36,000,000	$ 3,300,000	$ 3,800,000	$ 1,200,000	42,400,000
Note receivable future payment, reserve				$ 260,000	$ 260,000
Wisepower
Accounts Notes And Loans Receivable [Line Items]
Note Receivable, face amount							$ 2,500,000
Shares received as consideration for the sale of Note						1,570,000

Acquisitions - Summary of Estimated Fair Values at Date of Acquisition (Detail)	9 Months Ended
	Jun. 30, 2013 USD ($)
Roche
Business Acquisition [Line Items]
Current assets	$ 432,709
Property and equipment	7,215,206
Intangible assets	1,174,935
Other noncurrent assets	6,264
Current liabilities	(414,122)
Noncurrent liabilities	(1,570,072)
Gain on purchase	(1,576,106)
Total purchase consideration	5,268,814
Alvos acquisition
Business Acquisition [Line Items]
Current assets	29,332
Current liabilities	(113,033)
Total purchase consideration	2,088,686
In-process R&D	$ 2,172,387

Acquisitions - Purchase Consideration (Detail) - USD ($)	Jun. 30, 2013	May 31, 2013	Sep. 30, 2012	Aug. 10, 2012	Apr. 15, 2012	Oct. 21, 2011	Sep. 30, 2011
Business Acquisition [Line Items]
Contingent consideration	$ 173,621		$ 173,621				$ 0
Sale of stock, price per share		$ 1.83		$ 2.76
Roche
Business Acquisition [Line Items]
Promissory note due Roche						$ 50,000
Contingent consideration						84,935
Shares issued						5,133,879
Total purchase consideration						$ 5,268,814
Alvos acquisition
Business Acquisition [Line Items]
Contingent consideration					$ 88,686
Shares issued					315,457
Total purchase consideration					$ 2,088,686
Sale of stock, price per share					$ 6.34
Share consideration					$ 2,000,000

- Definition

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 35
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910684&loc=d3e4570-128470

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4237-128469

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 30
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=18499824&loc=d3e4243-128469

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 40
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910732&loc=d3e4805-128471

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3642-128468

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 25
-Paragraph 27
-URI http://asc.fasb.org/extlink&oid=6946367&loc=d3e3629-128468

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(3),(c)(1)
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph g(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 29, 30, 41, 42, 64
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 65
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The acquisition-date fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination.

+ References + Details

- Definition

This element represents the acquisition-date fair value of the total consideration transferred which consists of the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer.

+ References + Details

Acquisitions - Additional Information (Detail) - USD ($)	1 Months Ended		9 Months Ended
	Apr. 30, 2012	Oct. 21, 2011	Jun. 30, 2013	Sep. 30, 2012	Apr. 15, 2012	Sep. 30, 2011
Business Acquisition [Line Items]
Obligation to pay royalties			Later of (i) the expiration of the last to expire patent right related to such product candidate that was transferred in the Transaction and (ii) ten years after the first commercial sale of such product candidate.
Net present value of contingent consideration		$ 84,935
Contingent consideration			$ 173,621	$ 173,621		$ 0
Roche
Business Acquisition [Line Items]
Issue of promissory note to Roche		$ 50,000
Issue of Common Stock		1,141,596
Applicable out-license term			90 days
Percentage of royalty liability			3.00%
Gain on purchase			$ 1,576,106
Contingent consideration		$ 84,935
Roche \| Minimum
Business Acquisition [Line Items]
Cash payments to Roche			2,500,000
Roche \| Maximum
Business Acquisition [Line Items]
Cash payments to Roche			$ 6,000,000
Alvos acquisition
Business Acquisition [Line Items]
Issue of Common Stock	315,457
Issue of additional shares of Common Stock, Value					$ 23,500,000
Contingent consideration					$ 88,686

Intangible Assets - Schedule of Intangible Asset (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended	122 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2013
Finite Lived And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization, beginning balance		$ 3,117,322
Intangible assets not subject to amortization, ending balance	$ 3,117,322	3,117,322	3,117,322	$ 3,117,322
Intangible assets not subject to amortization, Amortization	0	0		0
Intangible assets subject to amortization, beginning balance		1,667,247	1,731,211
Amortization		(222,345)	(293,964)
Intangible assets subject to amortization, ending balance	136,855	136,855	1,667,247	136,855
Impairment	(1,308,047)	(1,308,047)		(1,308,047)
FiniteAndIndefiniteLivedIntangibleAssetsNetBeginningBalance			1,731,211
Total Intangible assets, ending balance	$ 3,254,177	$ 3,254,177	4,784,569	$ 3,254,177
Madison acquisition
Finite Lived And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization, Additions			944,935
Intangible assets subject to amortization, Additions			230,000
Total Intangible assets, Additions			1,174,935
Alvos acquisition
Finite Lived And Indefinite Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization, Additions			2,172,387
Intangible assets subject to amortization, Additions
Total Intangible assets, Additions			$ 2,172,387

Intangible Assets - Additional Information (Detail)	3 Months Ended	9 Months Ended	122 Months Ended
Intangible Assets - Additional Information (Detail)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)
Expected Amortization Expense [Line Items]
Amortization period of intangible assets		12 years
Amortization of license agreements in 2013	$ 14,000	$ 14,000	$ 14,000
Amortization of license agreements in 2014	55,000	55,000	55,000
Amortization of license agreements in 2015	55,000	55,000	55,000
Amortization of license agreements in 2016	13,000	13,000	13,000
Amortization of license agreements in 2017	0	0	0
Amortization of license agreements, thereafter	0	0	0
Impairment expense	$ 1,308,047	$ 1,308,047	$ 1,308,047
Licensing Agreements
Expected Amortization Expense [Line Items]
Amortization period of intangible assets		4 years
Patents \| Minimum
Expected Amortization Expense [Line Items]
Amortization period of intangible assets		3 years
Patents \| Maximum
Expected Amortization Expense [Line Items]
Amortization period of intangible assets		20 years

Investment in Subsidiaries - Additional Information (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2011	Jan. 31, 2011
Schedule Of Investments [Line Items]
Ownership percentage in subsidiary	100.00%
Aggregate purchase price of preferred shares		$ 1,618,509
Preferred Stock B and C
Schedule Of Investments [Line Items]
Investment in preferred stock			$ 9,100,000
Calando Pharmaceuticals, Inc.
Schedule Of Investments [Line Items]
Cash investment in subsidiary			1,000,000
Investment in subsidiary through conversion of intercompany debt			$ 8,100,000
Amount owed by subsidiary	$ 3,900,000
Stated percentage of notes and advances	8.00%
Percentage of outstanding shares	79.00%
Percentage of investment ownership	76.00%
Ablaris Therapeutics, Inc.
Schedule Of Investments [Line Items]
Investment in preferred stock		1,300,000
Amount owed by subsidiary	$ 1,300,000
Percentage of outstanding shares	64.00%
Percentage of investment ownership	64.00%
Aggregate purchase price of preferred shares		2,900,000
Investment in preferred stock by outsider		$ 1,600,000
Leonardo Biosystems, Inc.
Schedule Of Investments [Line Items]
Amount owed by subsidiary	$ 858,000
Percentage of outstanding shares	3.00%

Notes Payable - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2011	Jun. 30, 2013	Sep. 30, 2009	Sep. 30, 2012	Nov. 26, 2008	Sep. 30, 2008
Class Of Stock [Line Items]
Unsecured Convertible Promissory Note Agreements			$ 2,500,000			$ 2,500,000
Investment in Notes offering					$ 800,000
Principal amount of Note not converted into shares					$ 500,000
Offering Note matured date		Nov. 26, 2013
New Note terms		Two times principal payment upon certain events
New note interest rate		10.00%
Offering Note maturity amount		$ 1,000,000
Offering Note discount		74,351
Note payable	$ 50,000	$ 50,000		$ 839,421
Long-term debt instrument due date	Oct. 17, 2014
Calando \| Series A Preferred Stock
Class Of Stock [Line Items]
Conversion of Notes and accrued interest in to share			2,950

Stockholders' Equity - Summary of Information About Warrants (Detail)	Jun. 30, 2013 $ / Warrant shares	Jan. 31, 2013 $ / Warrant
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	1.83	1.83
Number of Warrants \| shares	6,055,535
Warrant 1
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	70.60
Number of Warrants \| shares	94,897
Remaining Life in Years	3 years 10 months 24 days
Warrant 2
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	20.00
Number of Warrants \| shares	386,400
Remaining Life in Years	1 month 6 days
Warrant 3
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	5.00
Number of Warrants \| shares	1,155,023
Remaining Life in Years	1 year 4 months 24 days
Warrant 4
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	5.09
Number of Warrants \| shares	461,024
Remaining Life in Years	1 year 4 months 24 days
Warrant 5
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	1.38
Number of Warrants \| shares	322,150
Remaining Life in Years	2 years 6 months
Warrant 6
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	4.16
Number of Warrants \| shares	1,000
Remaining Life in Years	3 years 6 months
Warrant 7
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	3.25
Number of Warrants \| shares	1,695,654
Remaining Life in Years	3 years 1 month 6 days
Warrant 8
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	1.83
Number of Warrants \| shares	987,543
Remaining Life in Years	4 years 6 months
Warrant 9
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	2.83
Number of Warrants \| shares	79,013
Remaining Life in Years	3 years 1 month 6 days
Warrant 10
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	1.83
Number of Warrants \| shares	833,530
Remaining Life in Years	4 years 7 months 6 days
Warrant 11
Class Of Warrant Or Right [Line Items]
Exercise prices \| $ / Warrant	2.65
Number of Warrants \| shares	39,301
Remaining Life in Years	3 years 1 month 6 days

Stockholders' Equity - Additional Information (Detail)	1 Months Ended							3 Months Ended		9 Months Ended		12 Months Ended				122 Months Ended
Stockholders' Equity - Additional Information (Detail)	May 31, 2013 USD ($) $ / shares shares	Jan. 31, 2013 USD ($) $ / shares $ / Warrant shares	Dec. 31, 2012 USD ($) $ / shares shares	Aug. 10, 2012 USD ($) $ / shares shares	Feb. 29, 2012 shares	Oct. 31, 2011 USD ($) shares	Sep. 30, 2011 USD ($) $ / shares shares	Jun. 30, 2013 USD ($) $ / shares $ / Warrant shares	Dec. 31, 2012 USD ($) $ / shares shares	Jun. 30, 2013 USD ($) $ / shares $ / Warrant shares	Jun. 30, 2012 USD ($) shares	Sep. 30, 2012 $ / shares shares	Sep. 30, 2011 USD ($) $ / shares shares	Sep. 30, 2010 shares	Sep. 30, 2005 shares	Jun. 30, 2013 USD ($) $ / shares $ / Warrant shares	Oct. 24, 2011 $ / shares	Oct. 21, 2011 $ / shares	Oct. 04, 2011 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Capital stock authorized for issuance								150,000,000		150,000,000						150,000,000
Common stock, shares authorized								145,000,000		145,000,000		145,000,000				145,000,000
Common stock, par value \| $ / shares								$ 0.001		$ 0.001		$ 0.001				$ 0.001
Preferred stock, shares authorized								5,000,000		5,000,000		5,000,000				5,000,000
Preferred stock, par value \| $ / shares								$ 0.001		$ 0.001		$ 0.001				$ 0.001
Common stock, shares outstanding								31,306,318		31,306,318		13,579,185				31,306,318
Preferred stock, shares outstanding								9,900		9,900		9,900				9,900
Additional Share reserve for issuance of warrants outstanding								6,055,535		6,055,535						6,055,535
Issuance and sold of stock	14,300,000.0			2,260,869
Sale of stock, price per share \| $ / shares	$ 1.83			$ 2.76
Proceeds from issuance of common stock and warrants, net \| $	$ 35,400,000	$ 3,500,000		$ 6,200,000						$ 42,448,824	$ 5,401,392					$ 148,701,835
Aggregate purchase price of preferred shares \| $													$ 1,618,509
Warrant to purchase common stock				0.75
Common stock exercise price \| $ / shares				$ 3.25
Exercise price of warrant \| $ / Warrant		1.83						1.83		1.83						1.83
Unit sold, description		Each unit consisted of one share of Common Stock and a warrant to purchase	Each unit consisted of one share of Common Stock and a warrant to purchase
Shares issued under public offering		1,667,051	1,800,000.0					1,170,000
Shares issued under public offering, price per share \| $ / shares		$ 2.12	$ 2.26						$ 2.26
Warrant to purchase share of Common Stock		0.5	0.5						0.5
Conversion price \| $ / shares	$ 1.83
Gross proceeds from offering \| $	$ 36,000,000	$ 3,300,000	$ 3,800,000					$ 1,200,000		$ 42,400,000
Series A Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Preferred stock, par value \| $ / shares																	$ 0.001
Sale of stock, price per share \| $ / shares																	$ 1,000
Aggregate purchase price of preferred shares \| $						$ 1,015,000
Preferred stock converted to common stock, shares					275,782
Series B convertible preferred stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance and sold of stock	9,900
Sale of stock, price per share \| $ / shares	$ 1,000
Subscription Agreement
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance and sold of stock						675,000
Subscription Agreement \| Series A Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance and sold of stock											1,015
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance and sold of stock						138,158	1,191,473		1,825,079			15,511	8,656	225,189	1,250
Sale of stock, price per share \| $ / shares			$ 2.26				$ 3.80		$ 2.26				$ 3.80					$ 3.70	$ 3.80
Proceeds from issuance of common stock and warrants, net \| $						$ 525,000	$ 4,500,000		$ 4,100,000
Aggregate purchase price on issuance of common stock to be received \| $						$ 2,497,500
Warrant to purchase common stock									0.5
Exercise price of warrant \| $ / Warrant								1.83		1.83						1.83
2004 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share reserve for issuance								3,369,960		3,369,960						3,369,960
2000 Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share reserve for issuance								3,369,960		3,369,960						3,369,960

Leases - Future Minimum Lease Payments Under Capitalized Leases (Detail) - USD ($)	Jun. 30, 2013	Sep. 30, 2012
Capital Leased Assets [Line Items]
2013	$ 64,211
2014	256,846
2015	256,846
2016	256,846
2017	256,846
2018	256,846
2019 and thereafter	107,020
Less interest	(118,697)
Principal	1,336,764
Less current portion	(219,690)	$ (214,801)
Noncurrent portion	$ 1,117,074	$ 1,282,458

Leases - Future Minimum Lease Payments Under Operating Leases (Detail)	Jun. 30, 2013 USD ($)
Operating Leased Assets [Line Items]
2013	$ 94,661
2014	434,229
2015	445,921
2016	457,961
2017	470,154
2018	359,370
2019 and thereafter	125,415
Total	$ 2,387,711

Leases - Additional Information (Detail) - USD ($)	9 Months Ended		122 Months Ended
Leases - Additional Information (Detail) - USD ($)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Component Of Operating Other Cost And Expense [Line Items]
Rental expense			$ 4,532,000
Rental expenses include common area maintenance and real estate taxes	$ 13,000
Utilities costs per month	16,000
Increase in total monthly expenditures	72,000
Facility and equipment rent expense	407,000	$ 345,000
Pasadena, California
Component Of Operating Other Cost And Expense [Line Items]
Rental expense	13,000
Roche
Component Of Operating Other Cost And Expense [Line Items]
Rental expense	22,000
Monthly payments under capital lease	$ 21,000

Stock-Based Compensation - Summarize Information about Stock Options (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options Outstanding, Beginning Balance	1,910,794	729,096
Number of Options Outstanding, Granted	949,000	1,229,500
Number of Options Outstanding, Cancelled	0	(42,919)
Number of Options Outstanding, Exercised	0	(4,883)
Number of Options Outstanding, Ending Balance	2,859,794	1,910,794
Number of Options Outstanding, Exercisable, Ending Balance	1,129,939
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 6.01	$ 9.03
Weighted-Average Exercise Price Per Share, Granted	2.03	4.40
Weighted-Average Exercise Price Per Share, Cancelled	0	11.77
Weighted-Average Exercise Price Per Share, Exercised	0	5.20
Weighted-Average Exercise Price Per Share, Ending Balance	4.69	$ 6.01
Weighted-Average Exercise Price Per Share, Exercisable, Ending Balance	$ 7.01
Weighted-Average Remaining Contractual Term	8 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Exercisable	6 years 7 months 6 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Exercisable

Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) - $ / shares	9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield	0.00%
Volatility	69.00%
Weighted average grant date fair value per share of options granted	$ 1.26	$ 3.79
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	0.70%	0.90%
Volatility		90.00%
Expected life (in years)	5 years 6 months	5 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.25%	1.70%
Volatility		100.00%
Expected life (in years)	6 years 3 months	6 years 3 months

Stock-Based Compensation - Additional Information (Detail) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012	Sep. 30, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserve for issuance	6,055,535
Options granted and outstanding to purchase	2,859,794		1,910,794	729,096
Options granted outside of Equity Incentive plans	251,200
Options granted	949,000		1,229,500
Stock-based compensation expense	$ 1,114,375	$ 837,188
Fair value of the options granted	1,197,588	$ 3,505,912
Intrinsic value of the options exercised	$ 0
Stock options exercised	0		4,883
Dividend yield	0.00%
Calando Pharmaceuticals, Inc.
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of the options granted	$ 0	$ 33,690
Pre-tax compensation expense	$ 39,169
Weighted average period to recognize pre-tax compensation expense	2 years 2 months 12 days
Arrowhead
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Pre-tax compensation expense	$ 3,775,514
Weighted average period to recognize pre-tax compensation expense	2 years 10 months 24 days
2000 Stock Option Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserve for issuance	153,200
Options granted and outstanding to purchase	152,900
2004 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserve for issuance	2,965,860
Options granted and outstanding to purchase	2,455,694
Shares authorized for issuance	3,000,000
Shares available for issuance	510,166
Options granted	949,000

Fair Value Measurements & Derivative Instruments - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)

Jun. 30, 2013

Sep. 30, 2012

Sep. 30, 2011

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Marketable securities

$ 4,040,795

Derivative assets

30,011

$ 280,261

Contingent consideration

173,621

$ 0

Fair Value, Measurements, Recurring

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Cash and cash equivalents

29,025,930

3,377,288

Marketable securities

^[1]

4,040,795

106,500

Derivative assets

250,250

Derivative liabilities

2,335,163

647,213

Contingent consideration

173,621

Level 1 | Fair Value, Measurements, Recurring

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Cash and cash equivalents

29,025,930

3,377,288

Marketable securities

^[1]

4,040,795

106,500

Derivative assets

Level 2 | Fair Value, Measurements, Recurring

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Derivative assets

Level 3 | Fair Value, Measurements, Recurring

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Derivative assets

250,250

Derivative liabilities

2,335,163

647,213

Contingent consideration

$ 173,621

[1]	(1) Marketable securities at June 30, 2013 were comprised of investments classified as “held-to-maturity”, and are recorded at amortized cost on the Company’s Consolidated Balance Sheet.

Fair Value Measurements & Derivative Instruments - Assumptions Used in Valuing Derivative Asset (Detail) - Derivative asset	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2012
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk free interest rate		0.23%
Expected life	0 years	1 year 3 months 18 days
Dividend yield
Volatility	72.00%	72.00%

Fair Value Measurements & Derivative Instruments - Reconciliation of Derivative Asset (Detail) - Derivative asset - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2012
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Value, Beginning balance	$ 250,250	$ 161,125
Receipt of instruments
Change in value	(250,250)	89,125
Net settlements
Value, Ending balance		$ 250,250

Fair Value Measurements & Derivative Instruments - Assumptions Used in Valuing Derivative Liabilities (Detail)	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2012
2010 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk free interest rate	0.51%	0.31%
Expected life	2 years 6 months	3 years 2 months 12 days
Dividend yield
Volatility	69.00%	100.00%
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk free interest rate	1.41%
Expected life	4 years 6 months
Dividend yield
Volatility	69.00%
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk free interest rate	1.41%
Expected life	4 years 7 months 6 days
Dividend yield
Volatility	69.00%
Exchange rights
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Risk free interest rate	1.41%	0.62%
Expected life	4 years 6 months	5 years 3 months 18 days
Dividend yield
Volatility	0.69%	100.00%

Fair Value Measurements & Derivative Instruments - Reconciliation of Derivative Liability (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Jun. 30, 2013	Sep. 30, 2012	Sep. 30, 2011
Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Value, Beginning balance	$ 647,213	$ 944,980
Issuance of instruments	1,015,923
Change in value	(465,869)	(297,767)
Net settlements
Value, Ending balance	2,335,163	647,213	$ 944,980
Issuance of instruments	1,137,896
Exchange rights
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Value, Beginning balance	10,372	30,892
Change in value	(9,877)	(20,520)	(69,758)
Net settlements
Value, Ending balance	495	10,372	30,892
Issuance of instruments			$ 100,650

Fair Value Measurements & Derivative Investments - Change in Fair Value of Contingent Consideration Obligations (Detail)	12 Months Ended
	Sep. 30, 2012 USD ($)
Business Combinations [Abstract]
Value, Beginning balance	$ 0
Purchase price contingent consideration	173,621
Value, Ending balance	$ 173,621

- Definition

Fair value, as of the acquisition date, of potential payments under the contingent consideration arrangement including cash and shares.

+ References

+ Details

Fair Value Measurements & Derivative Instruments - Additional Information (Detail)	1 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2011 USD ($) $ / shares	Jun. 30, 2013 USD ($) shares	Sep. 30, 2012 USD ($)	Jan. 31, 2013 shares	Dec. 31, 2012 shares	Sep. 30, 2011 USD ($)	Jun. 30, 2010 shares
Fair Value Measurements Disclosure [Line Items]
Derivative assets		$ 30,011	$ 280,261
Warrants issued to acquire Common Stock \| shares				833,530	912,543		329,649
Warrants outstanding \| shares		322,150
Duration of exchange rights		7 years
Contingent consideration		$ 173,621	173,621			$ 0
Warrants
Fair Value Measurements Disclosure [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability		(465,869)	$ (297,767)
Unidym, Inc.
Fair Value Measurements Disclosure [Line Items]
Non cash consideration received in sale of interest in subsidiary, bonds	$ 2,500,000
Bond convertible conversion price per share \| $ / shares	$ 2.00
Loss from change in fair value of the derivative asset		250,250
Ablaris Therapeutics, Inc.
Fair Value Measurements Disclosure [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability		$ 9,877
Exchange right convertible conversion ratio for first year		0.06
Exchange right convertible conversion ratio for second year		0.04
Exchange right convertible conversion ratio for third year		0.03
Exchange right convertible conversion ratio for fourth year		0.02
Exchange right convertible conversion ratio for fifth year and beyond		0.01
Number of exchange right sold \| shares		675,000
Wisepower
Fair Value Measurements Disclosure [Line Items]
Derivative assets		$ 0

Subsequent Events - Additional Information (Detail)	3 Months Ended	9 Months Ended	122 Months Ended
Subsequent Events - Additional Information (Detail)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)
Subsequent Event [Line Items]
Net book value of patent	$ 1,300,000	$ 1,300,000	$ 1,300,000
Impairment expense	$ 1,308,047	$ 1,308,047	$ 1,308,047